{
  "trials": [
    {
      "identifier": "20050181",
      "pubmed": "24356622",
      "registration": "NR",
      "publication_date": "2014-01-01 00:00:00",
      "arms": 2,
      "disease": "colorectal_cancer",
      "subjects": 597,
      "weibull_by_arm": {
        "folfiri": {
          "scale": 7.776647599009686,
          "shape": 1.1285661111161989
        },
        "panitumumab_folfiri": {
          "scale": 9.43026502504777,
          "shape": 1.266902407896144
        }
      },
      "weibull_max_diff": 0.7959171308563324,
      "time_scale": "Months",
      "title": null,
      "condition_list": null,
      "data_index": null,
      "hazard_ratios": {
        "folfiri": {
          "panitumumab_folfiri": 0.8183406587758713
        },
        "panitumumab_folfiri": {
          "folfiri": 1.221984987884956
        }
      },
      "min_hazard_ratio": 0.8183406587758713
    },
    {
      "identifier": "A001",
      "pubmed": "25794890",
      "registration": "NCT00201851",
      "publication_date": "2015-03-20 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 499,
      "weibull_by_arm": {
        "a": {
          "scale": 11.81134773076356,
          "shape": 0.9873324580440057
        },
        "b": {
          "scale": 11.122639376529687,
          "shape": 1.3066611038641895
        }
      },
      "weibull_max_diff": 0.9698232864186046,
      "time_scale": "Unknown",
      "title": "Adjuvant Oophorectomy and Tamoxifen in Premenopausal Women With Hormone Receptor-Positive Breast Cancer",
      "condition_list": [
        "Breast Cancer"
      ],
      "data_index": {
        "age": [
          {
            "value_range": {
              "relation": "<",
              "lower": null,
              "upper": 44.0
            },
            "groups": [
              {
                "group_name": "Scheduled (A)",
                "count": 135,
                "percentage": 55.3
              },
              {
                "group_name": "Immediate (B)",
                "count": 140,
                "percentage": 54.9
              },
              {
                "group_name": "Nonrandomized (C)",
                "count": 131,
                "percentage": 57.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "≥",
              "lower": 44.0,
              "upper": null
            },
            "groups": [
              {
                "group_name": "Scheduled (A)",
                "count": 109,
                "percentage": 44.7
              },
              {
                "group_name": "Immediate (B)",
                "count": 115,
                "percentage": 45.1
              },
              {
                "group_name": "Nonrandomized (C)",
                "count": 99,
                "percentage": 43.0
              }
            ]
          }
        ],
        "ecog": []
      },
      "hazard_ratios": {
        "a": {
          "b": 0.8004482164254558
        },
        "b": {
          "a": 1.249300053994344
        }
      },
      "min_hazard_ratio": 0.8004482164254558
    },
    {
      "identifier": "A003",
      "pubmed": "25515658",
      "registration": "NR",
      "publication_date": "2014-12-15 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 156,
      "weibull_by_arm": {
        "control": {
          "scale": 31.836447352316892,
          "shape": 0.9682259526551558
        },
        "pci": {
          "scale": 44.2260260584848,
          "shape": 1.1599661661775416
        }
      },
      "weibull_max_diff": 0.6761950397264841,
      "time_scale": "Months",
      "title": null,
      "condition_list": null,
      "data_index": {
        "age": [],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "PCI",
                "count": 29,
                "percentage": 35.8
              },
              {
                "group_name": "Control",
                "count": 28,
                "percentage": 37.3
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "PCI",
                "count": 50,
                "percentage": 61.7
              },
              {
                "group_name": "Control",
                "count": 46,
                "percentage": 61.3
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 2.0,
              "upper": 2.0
            },
            "groups": [
              {
                "group_name": "PCI",
                "count": 2,
                "percentage": 2.5
              },
              {
                "group_name": "Control",
                "count": 1,
                "percentage": 1.3
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "control": {
          "pci": 0.6964213190503215
        },
        "pci": {
          "control": 1.4359123890171195
        }
      },
      "min_hazard_ratio": 0.6964213190503215
    },
    {
      "identifier": "A004",
      "pubmed": "24401928",
      "registration": "NCT00294996",
      "publication_date": "2014-01-08 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 363,
      "weibull_by_arm": {
        "mpt": {
          "scale": 21.76816126901653,
          "shape": 1.3171716027986091
        },
        "pt": {
          "scale": 19.290787784382715,
          "shape": 1.3891966638934463
        }
      },
      "weibull_max_diff": 0.8990702992102588,
      "time_scale": "Months",
      "title": "Trial of Myocet in Metastatic Breast Cancer",
      "condition_list": [
        "Breast Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "mpt": {
          "pt": 1.1678913682328038
        },
        "pt": {
          "mpt": 0.8562440199495189
        }
      },
      "min_hazard_ratio": 0.8562440199495189
    },
    {
      "identifier": "ACT1",
      "pubmed": "25385727",
      "registration": "NCT00547651",
      "publication_date": "2014-11-10 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 637,
      "weibull_by_arm": {
        "amrubicin": {
          "scale": 10.709136490382825,
          "shape": 1.2517906674639223
        },
        "topotecan": {
          "scale": 9.66215290584306,
          "shape": 1.37134740402304
        }
      },
      "weibull_max_diff": 0.9255615151609111,
      "time_scale": "Months",
      "title": "AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy",
      "condition_list": [
        "Small Cell Lung Cancer"
      ],
      "data_index": {
        "age": [
          {
            "value_range": {
              "relation": "≥",
              "lower": 65.0,
              "upper": null
            },
            "groups": [
              {
                "group_name": "Amrubicin",
                "count": 169,
                "percentage": 39.9
              },
              {
                "group_name": "Topotecan",
                "count": 74,
                "percentage": 34.7
              }
            ]
          },
          {
            "value_range": {
              "relation": "≥",
              "lower": 75.0,
              "upper": null
            },
            "groups": [
              {
                "group_name": "Amrubicin",
                "count": 32,
                "percentage": 7.5
              },
              {
                "group_name": "Topotecan",
                "count": 12,
                "percentage": 5.6
              }
            ]
          }
        ],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "Amrubicin",
                "count": 126,
                "percentage": 29.7
              },
              {
                "group_name": "Topotecan",
                "count": 72,
                "percentage": 33.8
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "Amrubicin",
                "count": 289,
                "percentage": 68.2
              },
              {
                "group_name": "Topotecan",
                "count": 137,
                "percentage": 64.3
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 2.0,
              "upper": 2.0
            },
            "groups": [
              {
                "group_name": "Amrubicin",
                "count": 9,
                "percentage": 2.1
              },
              {
                "group_name": "Topotecan",
                "count": 4,
                "percentage": 1.9
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "amrubicin": {
          "topotecan": 1.1396754952129853
        },
        "topotecan": {
          "amrubicin": 0.8774427494495857
        }
      },
      "min_hazard_ratio": 0.8774427494495857
    },
    {
      "identifier": "ACT2",
      "pubmed": "26483047",
      "registration": "NCT01229813",
      "publication_date": "2015-10-19 00:00:00",
      "arms": 2,
      "disease": "colorectal_cancer",
      "subjects": 67,
      "weibull_by_arm": {
        "mut_b": {
          "scale": 5.574648008897047,
          "shape": 1.701525321214657
        },
        "mut_c": {
          "scale": 5.0684004864697165,
          "shape": 1.7762242975432931
        }
      },
      "weibull_max_diff": 0.9174610450685504,
      "time_scale": "Months",
      "title": "Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.",
      "condition_list": [
        "Colorectal Cancer"
      ],
      "data_index": {
        "age": [],
        "ecog": [
          {
            "value_range": {
              "relation": "-",
              "lower": 0.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "ITT Total",
                "count": 157,
                "percentage": 68.0
              },
              {
                "group_name": "wt-B",
                "count": 27,
                "percentage": 77.0
              },
              {
                "group_name": "wt-BE",
                "count": 24,
                "percentage": 67.0
              },
              {
                "group_name": "mut-B",
                "count": 28,
                "percentage": 82.0
              },
              {
                "group_name": "mut-C",
                "count": 20,
                "percentage": 61.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 0.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "ITT Total",
                "count": 74,
                "percentage": 32.0
              },
              {
                "group_name": "wt-B",
                "count": 8,
                "percentage": 23.0
              },
              {
                "group_name": "wt-BE",
                "count": 12,
                "percentage": 33.0
              },
              {
                "group_name": "mut-B",
                "count": 6,
                "percentage": 18.0
              },
              {
                "group_name": "mut-C",
                "count": 13,
                "percentage": 39.0
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "mut_b": {
          "mut_c": 1.2001261381019788
        },
        "mut_c": {
          "mut_b": 0.8332457466358646
        }
      },
      "min_hazard_ratio": 0.8332457466358646
    },
    {
      "identifier": "ACTSCC",
      "pubmed": "24942277",
      "registration": "NCT00660894",
      "publication_date": "2014-06-18 00:00:00",
      "arms": 2,
      "disease": "colorectal_cancer",
      "subjects": 1518,
      "weibull_by_arm": {
        "s_1": {
          "scale": 11.545496016291935,
          "shape": 0.9597571221900297
        },
        "uft_lv": {
          "scale": 9.637350568138691,
          "shape": 0.9543646983524209
        }
      },
      "weibull_max_diff": 0.8329289749814315,
      "time_scale": "Unknown",
      "title": "Tegafur-Uracil and Leucovorin or S-1 in Treating Patients With Stage III Colon Cancer That Has Been Completely Removed by Surgery",
      "condition_list": [
        "Colorectal Cancer"
      ],
      "data_index": {
        "age": [
          {
            "value_range": {
              "relation": "≥",
              "lower": 70.0,
              "upper": null
            },
            "groups": [
              {
                "group_name": "S-1",
                "count": 279,
                "percentage": 36.8
              },
              {
                "group_name": "UFT/LV",
                "count": 257,
                "percentage": 33.8
              }
            ]
          }
        ],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "S-1",
                "count": 722,
                "percentage": 95.3
              },
              {
                "group_name": "UFT/LV",
                "count": 727,
                "percentage": 95.7
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "S-1",
                "count": 36,
                "percentage": 4.7
              },
              {
                "group_name": "UFT/LV",
                "count": 33,
                "percentage": 4.3
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "s_1": {
          "uft_lv": 1.1898769061915693
        },
        "uft_lv": {
          "s_1": 0.8404230679631354
        }
      },
      "min_hazard_ratio": 0.8404230679631354
    },
    {
      "identifier": "AIO0207",
      "pubmed": "26361971",
      "registration": "NCT00973609",
      "publication_date": "2015-09-09 00:00:00",
      "arms": 3,
      "disease": "colorectal_cancer",
      "subjects": 470,
      "weibull_by_arm": {
        "5fu_bev": {
          "scale": 27.034048781449098,
          "shape": 1.5612133262838768
        },
        "bev": {
          "scale": 27.969930778055094,
          "shape": 1.7386418657055023
        },
        "no_tx": {
          "scale": 28.622390416294785,
          "shape": 1.5973543457558492
        }
      },
      "weibull_max_diff": 0.9395034710100996,
      "time_scale": "Months",
      "title": "Optimal Maintenance Therapy With Bevacizumab After Induction in Metastatic Colorectal Cancer (CRC)",
      "condition_list": [
        "Colorectal Neoplasms"
      ],
      "data_index": {
        "age": [],
        "ecog": []
      },
      "hazard_ratios": {
        "5fu_bev": {
          "bev": 0.9337842736300257,
          "no_tx": 0.900599763062741
        },
        "bev": {
          "5fu_bev": 1.0709111603610166,
          "no_tx": 0.9691892534763462
        },
        "no_tx": {
          "5fu_bev": 1.110371155994113,
          "bev": 1.0317902271544386
        }
      },
      "min_hazard_ratio": 0.900599763062741
    },
    {
      "identifier": "ALTTO",
      "pubmed": "26598744",
      "registration": "NCT00490139",
      "publication_date": "2015-11-23 00:00:00",
      "arms": 4,
      "disease": "breast_cancer",
      "subjects": 8381,
      "weibull_by_arm": {
        "l": {
          "scale": 19.656605393095923,
          "shape": 1.0290529265697348
        },
        "l_t": {
          "scale": 22.871165315714535,
          "shape": 1.1958302528322529
        },
        "t": {
          "scale": 25.901530798000636,
          "shape": 1.0143190700447957
        },
        "t_then_l": {
          "scale": 28.956243718056477,
          "shape": 0.9864959795704985
        }
      },
      "weibull_max_diff": 0.6893489856727604,
      "time_scale": "Unknown",
      "title": "ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D",
      "condition_list": [
        "Neoplasms, Breast"
      ],
      "data_index": {
        "age": [
          {
            "value_range": {
              "relation": "<",
              "lower": null,
              "upper": 65.0
            },
            "groups": [
              {
                "group_name": "L+T",
                "count": 1879,
                "percentage": 90.0
              },
              {
                "group_name": "T→L",
                "count": 1877,
                "percentage": 90.0
              },
              {
                "group_name": "L",
                "count": 1889,
                "percentage": 90.0
              },
              {
                "group_name": "T",
                "count": 1881,
                "percentage": 90.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "≥",
              "lower": 65.0,
              "upper": null
            },
            "groups": [
              {
                "group_name": "L+T",
                "count": 214,
                "percentage": 10.0
              },
              {
                "group_name": "T→L",
                "count": 214,
                "percentage": 10.0
              },
              {
                "group_name": "L",
                "count": 211,
                "percentage": 10.0
              },
              {
                "group_name": "T",
                "count": 216,
                "percentage": 10.0
              }
            ]
          }
        ],
        "ecog": []
      },
      "hazard_ratios": {
        "l": {
          "l_t": 0.6445212135534971,
          "t": 0.7723756168712284,
          "t_then_l": 0.7309847098359135
        },
        "l_t": {
          "l": 1.5515393116180143,
          "t": 1.1979950648081523,
          "t_then_l": 1.1312447812355255
        },
        "t": {
          "l": 1.2947068474932468,
          "l_t": 0.8347279795849082,
          "t_then_l": 0.9441996215842547
        },
        "t_then_l": {
          "l": 1.3680176706082858,
          "l_t": 0.8839819786022064,
          "t": 1.0590980732677258
        }
      },
      "min_hazard_ratio": 0.6445212135534971
    },
    {
      "identifier": "AMAROS",
      "pubmed": "25439688",
      "registration": "NCT00014612",
      "publication_date": "2014-10-16 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 1425,
      "weibull_by_arm": {
        "dissection": {
          "scale": 272.8503225889016,
          "shape": 1.2592031866116276
        },
        "radiotherapy": {
          "scale": 232.38006522043548,
          "shape": 1.3005579507458338
        }
      },
      "weibull_max_diff": 0.8595950628519236,
      "time_scale": "Months",
      "title": "Comparison of Complete Axillary Lymph Node Dissection With Axillary Radiation Therapy in Treating Women With Invasive Breast Cancer",
      "condition_list": [
        "Breast Cancer"
      ],
      "data_index": {
        "age": [],
        "ecog": []
      },
      "hazard_ratios": {
        "dissection": {
          "radiotherapy": 1.1704172706961227
        },
        "radiotherapy": {
          "dissection": 0.854396141476309
        }
      },
      "min_hazard_ratio": 0.854396141476309
    },
    {
      "identifier": "ASPECCT",
      "pubmed": "24739896",
      "registration": "NCT01001377",
      "publication_date": "2014-04-14 00:00:00",
      "arms": 2,
      "disease": "colorectal_cancer",
      "subjects": 999,
      "weibull_by_arm": {
        "cetuximab": {
          "scale": 5.502211103814547,
          "shape": 1.3602008720048124
        },
        "panitumumab": {
          "scale": 5.4468401674637645,
          "shape": 1.3097107110657884
        }
      },
      "weibull_max_diff": 0.9797067047830609,
      "time_scale": "Months",
      "title": "ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer",
      "condition_list": [
        "Metastatic Colorectal Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "cetuximab": {
          "panitumumab": 1.0174876312299852
        },
        "panitumumab": {
          "cetuximab": 0.9828129299136094
        }
      },
      "min_hazard_ratio": 0.9828129299136094
    },
    {
      "identifier": "ATTENTION",
      "pubmed": "26153496",
      "registration": "NCT01377376",
      "publication_date": "2015-07-07 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 307,
      "weibull_by_arm": {
        "placebo": {
          "scale": 15.525300346192921,
          "shape": 1.2988138319371667
        },
        "tivantinib": {
          "scale": 17.327162654407616,
          "shape": 1.3003261870799425
        }
      },
      "weibull_max_diff": 0.8957153589560667,
      "time_scale": "Months",
      "title": "A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib",
      "condition_list": [
        "Non-small-cell Lung Cancer"
      ],
      "data_index": {
        "age": [],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "Placebo group",
                "count": 51,
                "percentage": 33.3
              },
              {
                "group_name": "Tivantinib group",
                "count": 66,
                "percentage": 42.9
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "Placebo group",
                "count": 102,
                "percentage": 66.7
              },
              {
                "group_name": "Tivantinib group",
                "count": 88,
                "percentage": 57.1
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "placebo": {
          "tivantinib": 0.8622049282087932
        },
        "tivantinib": {
          "placebo": 1.1598170774521923
        }
      },
      "min_hazard_ratio": 0.8622049282087932
    },
    {
      "identifier": "AURA3",
      "pubmed": "27959700",
      "registration": "NCT02151981 ",
      "publication_date": "2016-12-06 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 419,
      "weibull_by_arm": {
        "osimertinib": {
          "scale": 12.954414214952452,
          "shape": 1.4331006976797775
        },
        "platinum-pemetrexed": {
          "scale": 6.31946439905115,
          "shape": 1.5014837987151988
        }
      },
      "weibull_max_diff": 0.4935384926557388,
      "time_scale": "Unknown",
      "title": null,
      "condition_list": null,
      "data_index": {
        "age": [],
        "ecog": []
      },
      "hazard_ratios": {
        "osimertinib": {
          "platinum-pemetrexed": 2.705936806409041
        },
        "platinum-pemetrexed": {
          "osimertinib": 0.3695577803707345
        }
      },
      "min_hazard_ratio": 0.3695577803707345
    },
    {
      "identifier": "AZURE",
      "pubmed": "25035292",
      "registration": "NCT00072020",
      "publication_date": "2014-07-15 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 3359,
      "weibull_by_arm": {
        "control": {
          "scale": 235.2572936858909,
          "shape": 0.9990223306742869
        },
        "zoledronic_acid": {
          "scale": 235.61091635018633,
          "shape": 1.0584118187787335
        }
      },
      "weibull_max_diff": 0.9781542886513478,
      "time_scale": "Months",
      "title": "Chemotherapy and/or Hormone Therapy With or Without Zoledronate in Treating Women With Stage II or Stage III Breast Cancer",
      "condition_list": [
        "Breast Cancer",
        "Metastatic Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "control": {
          "zoledronic_acid": 0.9362441933525788
        },
        "zoledronic_acid": {
          "control": 1.0680974120855378
        }
      },
      "min_hazard_ratio": 0.9362441933525788
    },
    {
      "identifier": "BEACON",
      "pubmed": "26482278",
      "registration": "NCT01492101",
      "publication_date": "2015-10-16 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 852,
      "weibull_by_arm": {
        "control": {
          "scale": 14.717470528524164,
          "shape": 1.2283456927386625
        },
        "etirinotecan_pegol": {
          "scale": 16.339080275100002,
          "shape": 1.4185378822025332
        }
      },
      "weibull_max_diff": 0.8654288557325618,
      "time_scale": "Months",
      "title": "The BEACON Study (Breast Cancer Outcomes With NKTR-102)",
      "condition_list": [
        "Locally Recurrent Breast Cancer",
        "Metastatic Breast Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "control": {
          "etirinotecan_pegol": 0.8655932754301117
        },
        "etirinotecan_pegol": {
          "control": 1.1552769971590895
        }
      },
      "min_hazard_ratio": 0.8655932754301117
    },
    {
      "identifier": "BEBYP",
      "pubmed": "25600568",
      "registration": "NCT00720512",
      "publication_date": "2015-01-18 00:00:00",
      "arms": 2,
      "disease": "colorectal_cancer",
      "subjects": 184,
      "weibull_by_arm": {
        "bev_ct": {
          "scale": 7.257403328502776,
          "shape": 1.4485582988101162
        },
        "ct": {
          "scale": 6.047594768471415,
          "shape": 1.4436054062693404
        }
      },
      "weibull_max_diff": 0.8325770153542781,
      "time_scale": "Months",
      "title": "Second-Line Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Who Have Received First-Line Chemotherapy and Bevacizumab",
      "condition_list": [
        "Colorectal Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "bev_ct": {
          "ct": 1.4150537989983927
        },
        "ct": {
          "bev_ct": 0.706686912333526
        }
      },
      "min_hazard_ratio": 0.706686912333526
    },
    {
      "identifier": "BEYOND",
      "pubmed": "26014294",
      "registration": "NCT01364012",
      "publication_date": "2015-05-26 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 276,
      "weibull_by_arm": {
        "bev_cp": {
          "scale": 31.292249414574883,
          "shape": 1.5888164898819073
        },
        "placebo_cp": {
          "scale": 23.544593024134937,
          "shape": 1.7059294390513422
        }
      },
      "weibull_max_diff": 0.764420125437896,
      "time_scale": "Months",
      "title": "A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy",
      "condition_list": [
        "Non-Small Cell Lung Cancer"
      ],
      "data_index": {
        "age": [],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "B+CP",
                "count": 34,
                "percentage": 25.0
              },
              {
                "group_name": "PI+CP",
                "count": 27,
                "percentage": 20.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "B+CP",
                "count": 104,
                "percentage": 75.0
              },
              {
                "group_name": "PI+CP",
                "count": 111,
                "percentage": 80.0
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "bev_cp": {
          "placebo_cp": 1.5511110138158408
        },
        "placebo_cp": {
          "bev_cp": 0.6446991808406611
        }
      },
      "min_hazard_ratio": 0.6446991808406611
    },
    {
      "identifier": "BOLERO1",
      "pubmed": "26092818",
      "registration": "NCT00876395",
      "publication_date": "2015-06-17 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 719,
      "weibull_by_arm": {
        "everolimus": {
          "scale": 30.669402050817386,
          "shape": 1.1538518355387186
        },
        "placebo": {
          "scale": 27.32036031922851,
          "shape": 1.198954853556179
        }
      },
      "weibull_max_diff": 0.9015101561499155,
      "time_scale": "Unknown",
      "title": "Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer",
      "condition_list": [
        "Breast Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "everolimus": {
          "placebo": 1.1376701160834315
        },
        "placebo": {
          "everolimus": 0.8789894239664326
        }
      },
      "min_hazard_ratio": 0.8789894239664326
    },
    {
      "identifier": "BOLERO2",
      "pubmed": "25231953",
      "registration": "NCT00863655",
      "publication_date": "2014-09-17 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 724,
      "weibull_by_arm": {
        "eve_exe": {
          "scale": 40.252950981142035,
          "shape": 1.370983337706751
        },
        "pbo_exe": {
          "scale": 38.02741568762068,
          "shape": 1.2477520359095797
        }
      },
      "weibull_max_diff": 0.9200946398057402,
      "time_scale": "Months",
      "title": "Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole",
      "condition_list": [
        "Breast Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "eve_exe": {
          "pbo_exe": 1.10886534689736
        },
        "pbo_exe": {
          "eve_exe": 0.9018227531395324
        }
      },
      "min_hazard_ratio": 0.9018227531395324
    },
    {
      "identifier": "BREC",
      "pubmed": "25164908",
      "registration": "NCT00617656",
      "publication_date": "2014-08-27 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 124,
      "weibull_by_arm": {
        "control": {
          "scale": 7.0329635921487235,
          "shape": 1.2319520547359775
        },
        "experimental": {
          "scale": 7.2491701070782275,
          "shape": 1.1151955454306737
        }
      },
      "weibull_max_diff": 0.9991315214656907,
      "time_scale": "Unknown",
      "title": "Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung Carcinoma",
      "condition_list": [
        "Non Small Cell Lung Cancer",
        "BRCA1 Mutation"
      ],
      "data_index": {
        "age": [],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "All patients",
                "count": 93,
                "percentage": 33.3
              },
              {
                "group_name": "Control arm",
                "count": 44,
                "percentage": 31.0
              },
              {
                "group_name": "Experimental arm",
                "count": 49,
                "percentage": 35.8
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "All patients",
                "count": 186,
                "percentage": 66.7
              },
              {
                "group_name": "Control arm",
                "count": 98,
                "percentage": 69.0
              },
              {
                "group_name": "Experimental arm",
                "count": 88,
                "percentage": 64.2
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "control": {
          "experimental": 0.96469794487325
        },
        "experimental": {
          "control": 1.036593894818951
        }
      },
      "min_hazard_ratio": 0.96469794487325
    },
    {
      "identifier": "CA184043",
      "pubmed": "24831977",
      "registration": "NCT00861614",
      "publication_date": "2014-05-13 00:00:00",
      "arms": 2,
      "disease": "prostate_cancer",
      "subjects": 799,
      "weibull_by_arm": {
        "ipilimumab": {
          "scale": 16.78510676175935,
          "shape": 1.0711093021697695
        },
        "placebo": {
          "scale": 14.30917127818776,
          "shape": 1.3915602005730698
        }
      },
      "weibull_max_diff": 0.9223842844941835,
      "time_scale": "Months",
      "title": "Study of Immunotherapy to Treat Advanced Prostate Cancer",
      "condition_list": [
        "Prostate Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "ipilimumab": {
          "placebo": 1.1722804477123434
        },
        "placebo": {
          "ipilimumab": 0.8530381974308779
        }
      },
      "min_hazard_ratio": 0.8530381974308779
    },
    {
      "identifier": "CA184095",
      "pubmed": "28034081",
      "registration": "NCT01057810",
      "publication_date": "2016-10-10 00:00:00",
      "arms": 2,
      "disease": "prostate_cancer",
      "subjects": 602,
      "weibull_by_arm": {
        "ipilimumab": {
          "scale": 10.558305971936788,
          "shape": 1.0499210831956127
        },
        "placebo": {
          "scale": 6.999802766247194,
          "shape": 1.0530702685600735
        }
      },
      "weibull_max_diff": 0.663658918418058,
      "time_scale": "Months",
      "title": "Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer",
      "condition_list": [
        "Prostate Cancer"
      ],
      "data_index": {
        "age": [
          {
            "value_range": {
              "relation": "<",
              "lower": null,
              "upper": 65.0
            },
            "groups": [
              {
                "group_name": "Ipilimumab",
                "count": 104,
                "percentage": 26.0
              },
              {
                "group_name": "Placebo",
                "count": 65,
                "percentage": 32.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "≥",
              "lower": 65.0,
              "upper": null
            },
            "groups": [
              {
                "group_name": "Ipilimumab",
                "count": 296,
                "percentage": 74.0
              },
              {
                "group_name": "Placebo",
                "count": 137,
                "percentage": 68.0
              }
            ]
          }
        ],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "Ipilimumab",
                "count": 299,
                "percentage": 75.0
              },
              {
                "group_name": "Placebo",
                "count": 151,
                "percentage": 75.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "Ipilimumab",
                "count": 100,
                "percentage": 25.0
              },
              {
                "group_name": "Placebo",
                "count": 51,
                "percentage": 25.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 2.0,
              "upper": 2.0
            },
            "groups": [
              {
                "group_name": "Ipilimumab",
                "count": 1,
                "percentage": null
              },
              {
                "group_name": "Placebo",
                "count": 0,
                "percentage": 0.0
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "ipilimumab": {
          "placebo": 1.5219072840015455
        },
        "placebo": {
          "ipilimumab": 0.6570702502787841
        }
      },
      "min_hazard_ratio": 0.6570702502787841
    },
    {
      "identifier": "CAIRO3",
      "pubmed": "25862517",
      "registration": "NCT00442637",
      "publication_date": "2015-04-08 00:00:00",
      "arms": 2,
      "disease": "colorectal_cancer",
      "subjects": 557,
      "weibull_by_arm": {
        "maintenance": {
          "scale": 12.828816113899292,
          "shape": 1.0899122632155613
        },
        "observation": {
          "scale": 6.071903026592062,
          "shape": 1.0920172852747656
        }
      },
      "weibull_max_diff": 0.4736088037982093,
      "time_scale": "Months",
      "title": "Maintenance Treatment Versus Observation After Induction in Advanced Colorectal Carcinoma",
      "condition_list": [
        "Colorectal Cancer Metastatic"
      ],
      "data_index": null,
      "hazard_ratios": {
        "maintenance": {
          "observation": 2.2146382386078995
        },
        "observation": {
          "maintenance": 0.45154101584942846
        }
      },
      "min_hazard_ratio": 0.45154101584942846
    },
    {
      "identifier": "CALGB40502",
      "pubmed": "26056183",
      "registration": "NCT00785291",
      "publication_date": "2015-06-08 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 487,
      "weibull_by_arm": {
        "ixabepilone": {
          "scale": 11.453262768158037,
          "shape": 1.1846461706917943
        },
        "paclitaxel": {
          "scale": 16.873345343689127,
          "shape": 1.3008339858946707
        }
      },
      "weibull_max_diff": 0.6602780462944249,
      "time_scale": "Months",
      "title": "Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer",
      "condition_list": [
        "Estrogen Receptor Negative",
        "Estrogen Receptor Positive",
        "HER2/Neu Negative",
        "HER2/Neu Positive",
        "Progesterone Receptor Negative",
        "Progesterone Receptor Positive",
        "Recurrent Breast Carcinoma",
        "Stage IIIC Breast Cancer AJCC v6",
        "Stage IV Breast Cancer AJCC v6 and v7"
      ],
      "data_index": {
        "age": [
          {
            "value_range": {
              "relation": "-",
              "lower": 20.0,
              "upper": 49.0
            },
            "groups": [
              {
                "group_name": "Paclitaxel",
                "count": 69,
                "percentage": 24.0
              },
              {
                "group_name": "Nab-Paclitaxel",
                "count": 76,
                "percentage": 28.0
              },
              {
                "group_name": "Ixabepilone",
                "count": 73,
                "percentage": 30.0
              },
              {
                "group_name": "Total",
                "count": 218,
                "percentage": 27.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 50.0,
              "upper": 69.0
            },
            "groups": [
              {
                "group_name": "Paclitaxel",
                "count": 183,
                "percentage": 66.0
              },
              {
                "group_name": "Nab-Paclitaxel",
                "count": 163,
                "percentage": 60.0
              },
              {
                "group_name": "Ixabepilone",
                "count": 154,
                "percentage": 63.0
              },
              {
                "group_name": "Total",
                "count": 500,
                "percentage": 63.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 70.0,
              "upper": 80.0
            },
            "groups": [
              {
                "group_name": "Paclitaxel",
                "count": 31,
                "percentage": 11.0
              },
              {
                "group_name": "Nab-Paclitaxel",
                "count": 32,
                "percentage": 12.0
              },
              {
                "group_name": "Ixabepilone",
                "count": 18,
                "percentage": 7.0
              },
              {
                "group_name": "Total",
                "count": 81,
                "percentage": 10.0
              }
            ]
          }
        ],
        "ecog": []
      },
      "hazard_ratios": {
        "ixabepilone": {
          "paclitaxel": 0.6352754680859464
        },
        "paclitaxel": {
          "ixabepilone": 1.5741202836195618
        }
      },
      "min_hazard_ratio": 0.6352754680859464
    },
    {
      "identifier": "CALGB40503",
      "pubmed": "27138575",
      "registration": "NCT00601900",
      "publication_date": "2016-08-01 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 343,
      "weibull_by_arm": {
        "l": {
          "scale": 53.739310680664246,
          "shape": 1.5854018073519571
        },
        "l_b": {
          "scale": 58.66738600905614,
          "shape": 1.6292560479437577
        }
      },
      "weibull_max_diff": 0.9103175392891053,
      "time_scale": "Months",
      "title": "Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer",
      "condition_list": [
        "Invasive Breast Carcinoma",
        "Recurrent Breast Carcinoma",
        "Stage III Breast Cancer AJCC v6",
        "Stage IV Breast Cancer AJCC v6 and v7"
      ],
      "data_index": {
        "age": [
          {
            "value_range": {
              "relation": "<",
              "lower": null,
              "upper": 30.0
            },
            "groups": [
              {
                "group_name": "Letrozole + Bevacizumab",
                "count": 1,
                "percentage": 1.0
              },
              {
                "group_name": "Letrozole",
                "count": 1,
                "percentage": 1.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 31.0,
              "upper": 40.0
            },
            "groups": [
              {
                "group_name": "Letrozole + Bevacizumab",
                "count": 17,
                "percentage": 10.0
              },
              {
                "group_name": "Letrozole",
                "count": 13,
                "percentage": 8.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 41.0,
              "upper": 50.0
            },
            "groups": [
              {
                "group_name": "Letrozole + Bevacizumab",
                "count": 35,
                "percentage": 20.0
              },
              {
                "group_name": "Letrozole",
                "count": 25,
                "percentage": 15.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 51.0,
              "upper": 60.0
            },
            "groups": [
              {
                "group_name": "Letrozole + Bevacizumab",
                "count": 53,
                "percentage": 31.0
              },
              {
                "group_name": "Letrozole",
                "count": 54,
                "percentage": 32.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 61.0,
              "upper": 70.0
            },
            "groups": [
              {
                "group_name": "Letrozole + Bevacizumab",
                "count": 53,
                "percentage": 31.0
              },
              {
                "group_name": "Letrozole",
                "count": 59,
                "percentage": 35.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 71.0,
              "upper": 80.0
            },
            "groups": [
              {
                "group_name": "Letrozole + Bevacizumab",
                "count": 17,
                "percentage": 10.0
              },
              {
                "group_name": "Letrozole",
                "count": 8,
                "percentage": 5.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "≥",
              "lower": 80.0,
              "upper": null
            },
            "groups": [
              {
                "group_name": "Letrozole + Bevacizumab",
                "count": 5,
                "percentage": 3.0
              },
              {
                "group_name": "Letrozole",
                "count": 5,
                "percentage": 3.0
              }
            ]
          }
        ],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "Letrozole + Bevacizumab",
                "count": 106,
                "percentage": 61.0
              },
              {
                "group_name": "Letrozole",
                "count": 101,
                "percentage": 59.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "Letrozole + Bevacizumab",
                "count": 64,
                "percentage": 37.0
              },
              {
                "group_name": "Letrozole",
                "count": 64,
                "percentage": 38.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 2.0,
              "upper": 2.0
            },
            "groups": [
              {
                "group_name": "Letrozole + Bevacizumab",
                "count": 3,
                "percentage": 2.0
              },
              {
                "group_name": "Letrozole",
                "count": 2,
                "percentage": 1.0
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "l": {
          "l_b": 0.8570638966364913
        },
        "l_b": {
          "l": 1.1667741505907023
        }
      },
      "min_hazard_ratio": 0.8570638966364913
    },
    {
      "identifier": "CALGB90202",
      "pubmed": "24590644",
      "registration": "NCT00079001",
      "publication_date": "2014-03-03 00:00:00",
      "arms": 2,
      "disease": "prostate_cancer",
      "subjects": 645,
      "weibull_by_arm": {
        "placebo": {
          "scale": 49.272457490664934,
          "shape": 1.475336995963079
        },
        "za": {
          "scale": 56.07999088707003,
          "shape": 1.3276385891996736
        }
      },
      "weibull_max_diff": 0.903231284329094,
      "time_scale": "Months",
      "title": "Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases",
      "condition_list": [
        "Metastatic Cancer",
        "Prostate Cancer"
      ],
      "data_index": {
        "age": [],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "Zoledronic acid",
                "count": 205,
                "percentage": 63.0
              },
              {
                "group_name": "Placebo",
                "count": 205,
                "percentage": 64.0
              },
              {
                "group_name": "Total",
                "count": 410,
                "percentage": 64.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "Zoledronic acid",
                "count": 105,
                "percentage": 33.0
              },
              {
                "group_name": "Placebo",
                "count": 109,
                "percentage": 34.0
              },
              {
                "group_name": "Total",
                "count": 214,
                "percentage": 33.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 2.0,
              "upper": 2.0
            },
            "groups": [
              {
                "group_name": "Zoledronic acid",
                "count": 13,
                "percentage": 4.0
              },
              {
                "group_name": "Placebo",
                "count": 8,
                "percentage": 2.0
              },
              {
                "group_name": "Total",
                "count": 21,
                "percentage": 3.0
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "placebo": {
          "za": 0.8871768312554618
        },
        "za": {
          "placebo": 1.1271710044376158
        }
      },
      "min_hazard_ratio": 0.8871768312554618
    },
    {
      "identifier": "CBCSG006",
      "pubmed": "25795409",
      "registration": "NCT01287624",
      "publication_date": "2015-03-18 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 236,
      "weibull_by_arm": {
        "cis_gemcitabine": {
          "scale": 10.159254000452579,
          "shape": 1.4955725751749833
        },
        "paclitaxel_gemcitabine": {
          "scale": 8.027172732363692,
          "shape": 1.5897568001928133
        }
      },
      "weibull_max_diff": 0.8016895146565828,
      "time_scale": "Months",
      "title": "Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Paclitaxel in Triple Negative Breast Cancer (TNBC)",
      "condition_list": [
        "Breast Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "cis_gemcitabine": {
          "paclitaxel_gemcitabine": 1.4181755975223733
        },
        "paclitaxel_gemcitabine": {
          "cis_gemcitabine": 0.7051312980896386
        }
      },
      "min_hazard_ratio": 0.7051312980896386
    },
    {
      "identifier": "CEREBEL",
      "pubmed": "25605838",
      "registration": "NCT00820222",
      "publication_date": "2015-01-20 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 540,
      "weibull_by_arm": {
        "lapatinib_cape": {
          "scale": 10.060329366778921,
          "shape": 1.418822509710969
        },
        "trastuzumab_cape": {
          "scale": 12.879045207556278,
          "shape": 1.4095223658997889
        }
      },
      "weibull_max_diff": 0.7824719102006609,
      "time_scale": "Unknown",
      "title": "Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer",
      "condition_list": [
        "Metastases, Brain"
      ],
      "data_index": {
        "age": [],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "Lapatinib plus Capecitabine",
                "count": 260,
                "percentage": 96.0
              },
              {
                "group_name": "Trastuzumab plus Capecitabine",
                "count": 261,
                "percentage": 98.0
              },
              {
                "group_name": "Total",
                "count": 521,
                "percentage": 96.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "Lapatinib plus Capecitabine",
                "count": 9,
                "percentage": 3.0
              },
              {
                "group_name": "Trastuzumab plus Capecitabine",
                "count": 5,
                "percentage": 2.0
              },
              {
                "group_name": "Total",
                "count": 14,
                "percentage": 3.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 2.0,
              "upper": 2.0
            },
            "groups": [
              {
                "group_name": "Lapatinib plus Capecitabine",
                "count": 2,
                "percentage": 1.0
              },
              {
                "group_name": "Trastuzumab plus Capecitabine",
                "count": 3,
                "percentage": 1.0
              },
              {
                "group_name": "Total",
                "count": 5,
                "percentage": 1.0
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "lapatinib_cape": {
          "trastuzumab_cape": 0.7296869619349212
        },
        "trastuzumab_cape": {
          "lapatinib_cape": 1.3704506893590176
        }
      },
      "min_hazard_ratio": 0.7296869619349212
    },
    {
      "identifier": "Checkmate017",
      "pubmed": "26028407",
      "registration": "NCT01642004",
      "publication_date": "2015-05-31 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 272,
      "weibull_by_arm": {
        "docetaxel": {
          "scale": 9.112779152943894,
          "shape": 1.1662903134752185
        },
        "nivolumab": {
          "scale": 15.244740284737507,
          "shape": 1.0517517175984938
        }
      },
      "weibull_max_diff": 0.6185770226099081,
      "time_scale": "Months",
      "title": "Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)",
      "condition_list": [
        "Squamous Cell Non-small Cell Lung Cancer"
      ],
      "data_index": {
        "age": [
          {
            "value_range": {
              "relation": "<",
              "lower": null,
              "upper": 65.0
            },
            "groups": [
              {
                "group_name": "Nivolumab",
                "count": 79,
                "percentage": 59.0
              },
              {
                "group_name": "Docetaxel",
                "count": 73,
                "percentage": 53.0
              },
              {
                "group_name": "Total",
                "count": 152,
                "percentage": 56.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 65.0,
              "upper": 75.0
            },
            "groups": [
              {
                "group_name": "Nivolumab",
                "count": 45,
                "percentage": 33.0
              },
              {
                "group_name": "Docetaxel",
                "count": 46,
                "percentage": 34.0
              },
              {
                "group_name": "Total",
                "count": 91,
                "percentage": 33.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "≥",
              "lower": 75.0,
              "upper": null
            },
            "groups": [
              {
                "group_name": "Nivolumab",
                "count": 11,
                "percentage": 8.0
              },
              {
                "group_name": "Docetaxel",
                "count": 18,
                "percentage": 13.0
              },
              {
                "group_name": "Total",
                "count": 29,
                "percentage": 11.0
              }
            ]
          }
        ],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "Nivolumab",
                "count": 27,
                "percentage": 20.0
              },
              {
                "group_name": "Docetaxel",
                "count": 37,
                "percentage": 27.0
              },
              {
                "group_name": "Total",
                "count": 64,
                "percentage": 24.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "Nivolumab",
                "count": 106,
                "percentage": 79.0
              },
              {
                "group_name": "Docetaxel",
                "count": 100,
                "percentage": 73.0
              },
              {
                "group_name": "Total",
                "count": 206,
                "percentage": 76.0
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "docetaxel": {
          "nivolumab": 0.588949662384394
        },
        "nivolumab": {
          "docetaxel": 1.697937979880058
        }
      },
      "min_hazard_ratio": 0.588949662384394
    },
    {
      "identifier": "Checkmate057",
      "pubmed": "26412456",
      "registration": "NCT01673867",
      "publication_date": "2015-09-27 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 582,
      "weibull_by_arm": {
        "docetaxel": {
          "scale": 5.730995957312953,
          "shape": 1.3391786533396461
        },
        "nivolumab": {
          "scale": 6.435667508019261,
          "shape": 0.8798282457513712
        }
      },
      "weibull_max_diff": 0.9734370061393168,
      "time_scale": "Months",
      "title": "Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC",
      "condition_list": [
        "Non-Squamous Cell Non-small Cell Lung Cancer"
      ],
      "data_index": {
        "age": [
          {
            "value_range": {
              "relation": "≥",
              "lower": 75.0,
              "upper": null
            },
            "groups": [
              {
                "group_name": "Nivolumab",
                "count": 20,
                "percentage": 7.0
              },
              {
                "group_name": "Docetaxel",
                "count": 23,
                "percentage": 8.0
              },
              {
                "group_name": "Total",
                "count": 43,
                "percentage": 7.0
              }
            ]
          }
        ],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "Nivolumab",
                "count": 84,
                "percentage": 29.0
              },
              {
                "group_name": "Docetaxel",
                "count": 95,
                "percentage": 33.0
              },
              {
                "group_name": "Total",
                "count": 179,
                "percentage": 31.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "Nivolumab",
                "count": 208,
                "percentage": 71.0
              },
              {
                "group_name": "Docetaxel",
                "count": 193,
                "percentage": 67.0
              },
              {
                "group_name": "Total",
                "count": 401,
                "percentage": 69.0
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "docetaxel": {
          "nivolumab": 0.9150004059212293
        },
        "nivolumab": {
          "docetaxel": 1.0928956900223366
        }
      },
      "min_hazard_ratio": 0.9150004059212293
    },
    {
      "identifier": "CHHiP",
      "pubmed": "27339115",
      "registration": "ISRCTN97182923",
      "publication_date": "2016-06-20 00:00:00",
      "arms": 3,
      "disease": "prostate_cancer",
      "subjects": 3216,
      "weibull_by_arm": {
        "57gy": {
          "scale": 190.27205537244572,
          "shape": 1.6705715107544987
        },
        "60gy": null,
        "74gy": {
          "scale": 251.43855805787902,
          "shape": 1.4765482043346796
        }
      },
      "weibull_max_diff": null,
      "time_scale": "Months",
      "title": null,
      "condition_list": null,
      "data_index": null,
      "hazard_ratios": {
        "57gy": {
          "60gy": 0.6779658507740692,
          "74gy": 0.8231949689002638
        },
        "60gy": {
          "57gy": 1.4750005459098594,
          "74gy": 1.190127300450831
        },
        "74gy": {
          "57gy": 1.2147790472236928,
          "60gy": 0.8402462489694951
        }
      },
      "min_hazard_ratio": 0.6779658507740692
    },
    {
      "identifier": "Chronicle",
      "pubmed": "24718885",
      "registration": "NCT00427713",
      "publication_date": "2014-04-08 00:00:00",
      "arms": 2,
      "disease": "colorectal_cancer",
      "subjects": 113,
      "weibull_by_arm": {
        "capecitabine_oxaliplatin": {
          "scale": 170.6727869516311,
          "shape": 1.3825223323242297
        },
        "follow_up_only": {
          "scale": 305.16528094915503,
          "shape": 1.0680570804849523
        }
      },
      "weibull_max_diff": 0.6046827689536184,
      "time_scale": "Months",
      "title": "Capecitabine and Oxaliplatin or Standard Follow-Up Care in Treating Patients Who Have Undergone Surgery for Locally Advanced Rectal Cancer",
      "condition_list": [
        "Colorectal Cancer"
      ],
      "data_index": {
        "age": [],
        "ecog": []
      },
      "hazard_ratios": {
        "capecitabine_oxaliplatin": {
          "follow_up_only": 0.8287623903552926
        },
        "follow_up_only": {
          "capecitabine_oxaliplatin": 1.2066184610178765
        }
      },
      "min_hazard_ratio": 0.8287623903552926
    },
    {
      "identifier": "CLEOPATRA",
      "pubmed": "25693012",
      "registration": "NCT00567190",
      "publication_date": "2015-02-19 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 808,
      "weibull_by_arm": {
        "control": {
          "scale": 21.90037495630407,
          "shape": 1.0371771226392956
        },
        "pertuzumab": {
          "scale": 32.530292603125,
          "shape": 1.0656198090782358
        }
      },
      "weibull_max_diff": 0.6669101186305192,
      "time_scale": "Months",
      "title": "A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer",
      "condition_list": [
        "Metastatic Breast Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "control": {
          "pertuzumab": 0.6675805476564973
        },
        "pertuzumab": {
          "control": 1.4979465826415133
        }
      },
      "min_hazard_ratio": 0.6675805476564973
    },
    {
      "identifier": "COMET1",
      "pubmed": "27400947",
      "registration": "NCT01605227",
      "publication_date": "2016-07-11 00:00:00",
      "arms": 2,
      "disease": "prostate_cancer",
      "subjects": 1028,
      "weibull_by_arm": {
        "cabozantinib": {
          "scale": 7.786872705024262,
          "shape": 1.652848951503562
        },
        "prednisone": {
          "scale": 4.9324148084156905,
          "shape": 1.7231688544499177
        }
      },
      "weibull_max_diff": 0.6391848937521186,
      "time_scale": "Months",
      "title": "Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100",
      "condition_list": [
        "Prostate Cancer",
        "Castration Resistant Prostate Cancer",
        "Pain",
        "Prostatic Neoplasms"
      ],
      "data_index": {
        "age": [],
        "ecog": [
          {
            "value_range": {
              "relation": "-",
              "lower": 0.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "Cabozantinib",
                "count": 605,
                "percentage": 89.0
              },
              {
                "group_name": "Prednisone",
                "count": 303,
                "percentage": 88.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 2.0,
              "upper": 2.0
            },
            "groups": [
              {
                "group_name": "Cabozantinib",
                "count": 76,
                "percentage": 11.0
              },
              {
                "group_name": "Prednisone",
                "count": 43,
                "percentage": 12.0
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "cabozantinib": {
          "prednisone": 2.032633185845251
        },
        "prednisone": {
          "cabozantinib": 0.4919726820184527
        }
      },
      "min_hazard_ratio": 0.4919726820184527
    },
    {
      "identifier": "CONCEPT",
      "pubmed": "24608198",
      "registration": "NR",
      "publication_date": "2014-03-07 00:00:00",
      "arms": 2,
      "disease": "colorectal_cancer",
      "subjects": 139,
      "weibull_by_arm": {
        "co": {
          "scale": 5.303166191232295,
          "shape": 1.5946088573817483
        },
        "io": {
          "scale": 7.673609194320178,
          "shape": 1.5189359639090754
        }
      },
      "weibull_max_diff": 0.6990505487707297,
      "time_scale": "Unknown",
      "title": null,
      "condition_list": null,
      "data_index": {
        "age": [
          {
            "value_range": {
              "relation": "<",
              "lower": null,
              "upper": 65.0
            },
            "groups": [
              {
                "group_name": "CO + Placebo",
                "count": 19,
                "percentage": null
              },
              {
                "group_name": "CO + Ca/Mg",
                "count": 20,
                "percentage": null
              },
              {
                "group_name": "IO + Placebo",
                "count": 21,
                "percentage": null
              },
              {
                "group_name": "IO + Ca/Mg",
                "count": 11,
                "percentage": null
              }
            ]
          },
          {
            "value_range": {
              "relation": "≥",
              "lower": 65.0,
              "upper": null
            },
            "groups": [
              {
                "group_name": "CO + Placebo",
                "count": 14,
                "percentage": null
              },
              {
                "group_name": "CO + Ca/Mg",
                "count": 15,
                "percentage": null
              },
              {
                "group_name": "IO + Placebo",
                "count": 15,
                "percentage": null
              },
              {
                "group_name": "IO + Ca/Mg",
                "count": 24,
                "percentage": null
              }
            ]
          }
        ],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "CO + Placebo",
                "count": 19,
                "percentage": null
              },
              {
                "group_name": "CO + Ca/Mg",
                "count": 17,
                "percentage": null
              },
              {
                "group_name": "IO + Placebo",
                "count": 22,
                "percentage": null
              },
              {
                "group_name": "IO + Ca/Mg",
                "count": 16,
                "percentage": null
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "CO + Placebo",
                "count": 13,
                "percentage": null
              },
              {
                "group_name": "CO + Ca/Mg",
                "count": 18,
                "percentage": null
              },
              {
                "group_name": "IO + Placebo",
                "count": 14,
                "percentage": null
              },
              {
                "group_name": "IO + Ca/Mg",
                "count": 19,
                "percentage": null
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "co": {
          "io": 0.5557993364245009
        },
        "io": {
          "co": 1.7992104964231794
        }
      },
      "min_hazard_ratio": 0.5557993364245009
    },
    {
      "identifier": "CONCUR",
      "pubmed": "25981818",
      "registration": "NCT01584830",
      "publication_date": "2015-05-14 00:00:00",
      "arms": 2,
      "disease": "colorectal_cancer",
      "subjects": 204,
      "weibull_by_arm": {
        "placebo": {
          "scale": 7.724940755547679,
          "shape": 1.6464811037062892
        },
        "regorafenib": {
          "scale": 11.605371988096163,
          "shape": 1.5544195142460562
        }
      },
      "weibull_max_diff": 0.6744686561626283,
      "time_scale": "Months",
      "title": "Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy",
      "condition_list": [
        "Colorectal Neoplasms"
      ],
      "data_index": null,
      "hazard_ratios": {
        "placebo": {
          "regorafenib": 0.5350282796518171
        },
        "regorafenib": {
          "placebo": 1.8690600815545206
        }
      },
      "min_hazard_ratio": 0.5350282796518171
    },
    {
      "identifier": "COUAA202",
      "pubmed": "25601341",
      "registration": "NCT00887198",
      "publication_date": "2015-01-16 00:00:00",
      "arms": 2,
      "disease": "prostate_cancer",
      "subjects": 1088,
      "weibull_by_arm": {
        "abiraterone": {
          "scale": 45.16614929076086,
          "shape": 1.732214224131743
        },
        "placebo": {
          "scale": 39.6036244782629,
          "shape": 1.8106349353594275
        }
      },
      "weibull_max_diff": 0.8849154255079716,
      "time_scale": "Months",
      "title": "Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer",
      "condition_list": [
        "Prostate Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "abiraterone": {
          "placebo": 1.2412887715393734
        },
        "placebo": {
          "abiraterone": 0.8056143122601993
        }
      },
      "min_hazard_ratio": 0.8056143122601993
    },
    {
      "identifier": "Dalotuzumab",
      "pubmed": "26405092",
      "registration": "NCT00614393",
      "publication_date": "2015-09-23 00:00:00",
      "arms": 3,
      "disease": "colorectal_cancer",
      "subjects": 344,
      "weibull_by_arm": {
        "arma": {
          "scale": 14.36551834216656,
          "shape": 1.3527967671040078
        },
        "armb": {
          "scale": 15.462423416957256,
          "shape": 1.6572212267851951
        },
        "armc": {
          "scale": 17.802527022316813,
          "shape": 1.549857874163799
        }
      },
      "weibull_max_diff": 0.7796128885376081,
      "time_scale": "Months",
      "title": "Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)",
      "condition_list": [
        "Metastatic Colorectal Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "arma": {
          "armb": 0.8634431943110108,
          "armc": 0.7225256820699413
        },
        "armb": {
          "arma": 1.1581537808030968,
          "armc": 0.8050678861838909
        },
        "armc": {
          "arma": 1.3840338479528245,
          "armb": 1.2421312750904872
        }
      },
      "min_hazard_ratio": 0.7225256820699413
    },
    {
      "identifier": "DART0105",
      "pubmed": "25702876",
      "registration": "NCT02175212",
      "publication_date": "2015-02-19 00:00:00",
      "arms": 2,
      "disease": "prostate_cancer",
      "subjects": 343,
      "weibull_by_arm": {
        "ltad": {
          "scale": 206.3522924393266,
          "shape": 1.8912691171196858
        },
        "stad": {
          "scale": 153.23490099992043,
          "shape": 1.8232880623046033
        }
      },
      "weibull_max_diff": 0.7372425533093419,
      "time_scale": "Unknown",
      "title": "Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer",
      "condition_list": [
        "Prostate Adenocarcinoma"
      ],
      "data_index": null,
      "hazard_ratios": {
        "ltad": {
          "stad": 1.8699429845694302
        },
        "stad": {
          "ltad": 0.5347756633501086
        }
      },
      "min_hazard_ratio": 0.5347756633501086
    },
    {
      "identifier": "DELTA",
      "pubmed": "24841974",
      "registration": "NR",
      "publication_date": "2014-05-19 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 301,
      "weibull_by_arm": {
        "docetaxel": {
          "scale": 18.334091455610373,
          "shape": 1.194655242817205
        },
        "erlotinib": {
          "scale": 20.292332269767748,
          "shape": 1.1091568551601763
        }
      },
      "weibull_max_diff": 0.9251199191063197,
      "time_scale": "Months",
      "title": null,
      "condition_list": null,
      "data_index": {
        "age": [],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "Erlotinib",
                "count": 77,
                "percentage": 51.3
              },
              {
                "group_name": "Docetaxel",
                "count": 78,
                "percentage": 51.7
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "Erlotinib",
                "count": 67,
                "percentage": 44.7
              },
              {
                "group_name": "Docetaxel",
                "count": 67,
                "percentage": 44.4
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 2.0,
              "upper": 2.0
            },
            "groups": [
              {
                "group_name": "Erlotinib",
                "count": 6,
                "percentage": 4.0
              },
              {
                "group_name": "Docetaxel",
                "count": 6,
                "percentage": 4.0
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "docetaxel": {
          "erlotinib": 0.906799758090535
        },
        "erlotinib": {
          "docetaxel": 1.1027792972791681
        }
      },
      "min_hazard_ratio": 0.906799758090535
    },
    {
      "identifier": "E1199",
      "pubmed": "26077235",
      "registration": "NCT00004125",
      "publication_date": "2015-06-15 00:00:00",
      "arms": 4,
      "disease": "breast_cancer",
      "subjects": 4948,
      "weibull_by_arm": {
        "d1": {
          "scale": 344.49816304236253,
          "shape": 1.2030560693271235
        },
        "d3": {
          "scale": 458.55432197130034,
          "shape": 1.077701885248766
        },
        "p1": {
          "scale": 346.1714023453911,
          "shape": 1.3292104876970967
        },
        "p3": {
          "scale": 365.3534267504893,
          "shape": 1.1444078139585707
        }
      },
      "weibull_max_diff": 0.7783693751571782,
      "time_scale": "Months",
      "title": "Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes",
      "condition_list": [
        "Breast Cancer"
      ],
      "data_index": {
        "age": [],
        "ecog": []
      },
      "hazard_ratios": {
        "d1": {
          "d3": 0.8379788529058525,
          "p1": 0.8681109568274208,
          "p3": 0.9914473742618535
        },
        "d3": {
          "d1": 1.1933475367932114,
          "p1": 1.0420977770787545,
          "p3": 1.1843336176218622
        },
        "p1": {
          "d1": 1.1519264814426229,
          "d3": 0.9596028530098543,
          "p3": 1.136070597394036
        },
        "p3": {
          "d1": 1.0086264041442583,
          "d3": 0.8443566788283833,
          "p1": 0.8802269879124061
        }
      },
      "min_hazard_ratio": 0.8379788529058525
    },
    {
      "identifier": "EAGLE",
      "pubmed": "25908603",
      "registration": "UMIN000002557",
      "publication_date": "2015-04-23 00:00:00",
      "arms": 2,
      "disease": "colorectal_cancer",
      "subjects": 368,
      "weibull_by_arm": {
        "bev10": {
          "scale": 8.47777953726576,
          "shape": 1.6918087142321863
        },
        "bev5": {
          "scale": 8.44713867777177,
          "shape": 1.558224669028484
        }
      },
      "weibull_max_diff": 0.9780514841452311,
      "time_scale": "Unknown",
      "title": null,
      "condition_list": null,
      "data_index": {
        "age": [],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
                "count": 155,
                "percentage": 86.0
              },
              {
                "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
                "count": 163,
                "percentage": 87.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
                "count": 26,
                "percentage": 14.0
              },
              {
                "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
                "count": 25,
                "percentage": 13.0
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "bev10": {
          "bev5": 0.9986909069063066
        },
        "bev5": {
          "bev10": 1.0013108090647873
        }
      },
      "min_hazard_ratio": 0.9986909069063066
    },
    {
      "identifier": "ELDA",
      "pubmed": "25488686",
      "registration": "NCT00331097",
      "publication_date": "2014-12-08 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 299,
      "weibull_by_arm": {
        "cmf": {
          "scale": 180.84274007190913,
          "shape": 0.9574196192570659
        },
        "wdocetaxel": {
          "scale": 134.66092059668705,
          "shape": 1.0547624286882595
        }
      },
      "weibull_max_diff": 0.771407507916668,
      "time_scale": "Months",
      "title": "ELDA: Elderly Breast Cancer - Docetaxel in Adjuvant Treatment",
      "condition_list": [
        "Breast Cancer"
      ],
      "data_index": {
        "age": [
          {
            "value_range": {
              "relation": "-",
              "lower": 65.0,
              "upper": 69.0
            },
            "groups": [
              {
                "group_name": "CMF",
                "count": 65,
                "percentage": 43.0
              },
              {
                "group_name": "Docetaxel",
                "count": 60,
                "percentage": 41.0
              },
              {
                "group_name": "Total",
                "count": 125,
                "percentage": 42.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 70.0,
              "upper": 74.0
            },
            "groups": [
              {
                "group_name": "CMF",
                "count": 54,
                "percentage": 36.0
              },
              {
                "group_name": "Docetaxel",
                "count": 51,
                "percentage": 35.0
              },
              {
                "group_name": "Total",
                "count": 105,
                "percentage": 35.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 75.0,
              "upper": 79.0
            },
            "groups": [
              {
                "group_name": "CMF",
                "count": 33,
                "percentage": 22.0
              },
              {
                "group_name": "Docetaxel",
                "count": 36,
                "percentage": 24.0
              },
              {
                "group_name": "Total",
                "count": 69,
                "percentage": 23.0
              }
            ]
          }
        ],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "CMF",
                "count": 127,
                "percentage": 84.0
              },
              {
                "group_name": "Docetaxel",
                "count": 120,
                "percentage": 82.0
              },
              {
                "group_name": "Total",
                "count": 247,
                "percentage": 83.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "CMF",
                "count": 25,
                "percentage": 16.0
              },
              {
                "group_name": "Docetaxel",
                "count": 27,
                "percentage": 18.0
              },
              {
                "group_name": "Total",
                "count": 52,
                "percentage": 17.0
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "cmf": {
          "wdocetaxel": 1.2261001369036086
        },
        "wdocetaxel": {
          "cmf": 0.8155940692783857
        }
      },
      "min_hazard_ratio": 0.8155940692783857
    },
    {
      "identifier": "ELM-PC4",
      "pubmed": "25701170",
      "registration": "NCT01193244",
      "publication_date": "2015-02-18 00:00:00",
      "arms": 2,
      "disease": "prostate_cancer",
      "subjects": 1560,
      "weibull_by_arm": {
        "orteronel": {
          "scale": 17.933949840200803,
          "shape": 1.4146927779124179
        },
        "placebo": {
          "scale": 13.84390440516696,
          "shape": 1.261886683676063
        }
      },
      "weibull_max_diff": 0.7480967867770324,
      "time_scale": "Months",
      "title": "Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer",
      "condition_list": [
        "Prostate Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "orteronel": {
          "placebo": 1.3944826598563949
        },
        "placebo": {
          "orteronel": 0.7171118213137057
        }
      },
      "min_hazard_ratio": 0.7171118213137057
    },
    {
      "identifier": "ELM-PC5",
      "pubmed": "25624429",
      "registration": "NCT01193257",
      "publication_date": "2015-01-26 00:00:00",
      "arms": 2,
      "disease": "prostate_cancer",
      "subjects": 1099,
      "weibull_by_arm": {
        "orteronel": {
          "scale": 11.243834879789542,
          "shape": 1.4411533782163686
        },
        "placebo": {
          "scale": 9.18271591101107,
          "shape": 1.3613320539775537
        }
      },
      "weibull_max_diff": 0.804600909588052,
      "time_scale": "Months",
      "title": "Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.",
      "condition_list": [
        "Prostate Cancer"
      ],
      "data_index": {
        "age": [
          {
            "value_range": {
              "relation": "≥",
              "lower": 70.0,
              "upper": null
            },
            "groups": [
              {
                "group_name": "Orteronel Plus Prednisone",
                "count": 367,
                "percentage": 50.0
              },
              {
                "group_name": "Placebo Plus Prednisone",
                "count": 194,
                "percentage": 53.0
              }
            ]
          }
        ],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "Orteronel Plus Prednisone",
                "count": null,
                "percentage": 42.0
              },
              {
                "group_name": "Placebo Plus Prednisone",
                "count": null,
                "percentage": 40.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "Orteronel Plus Prednisone",
                "count": null,
                "percentage": 50.0
              },
              {
                "group_name": "Placebo Plus Prednisone",
                "count": null,
                "percentage": 53.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 2.0,
              "upper": 2.0
            },
            "groups": [
              {
                "group_name": "Orteronel Plus Prednisone",
                "count": null,
                "percentage": 9.0
              },
              {
                "group_name": "Placebo Plus Prednisone",
                "count": null,
                "percentage": 7.0
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "orteronel": {
          "placebo": 1.3139647193921682
        },
        "placebo": {
          "orteronel": 0.761055441779741
        }
      },
      "min_hazard_ratio": 0.761055441779741
    },
    {
      "identifier": "ENSURE",
      "pubmed": "26105600",
      "registration": "NCT01342965",
      "publication_date": "2015-06-23 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 217,
      "weibull_by_arm": {
        "erlotinib": {
          "scale": 32.816507971096485,
          "shape": 1.67402553862252
        },
        "gp": {
          "scale": 31.389952770462006,
          "shape": 1.518813546090212
        }
      },
      "weibull_max_diff": 0.9353653845358364,
      "time_scale": "Months",
      "title": "A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations",
      "condition_list": [
        "Non-Small Cell Lung Cancer"
      ],
      "data_index": {
        "age": [
          {
            "value_range": {
              "relation": "<",
              "lower": null,
              "upper": 65.0
            },
            "groups": [
              {
                "group_name": "Erlotinib",
                "count": null,
                "percentage": 79.1
              },
              {
                "group_name": "GP",
                "count": null,
                "percentage": 79.4
              }
            ]
          },
          {
            "value_range": {
              "relation": "≥",
              "lower": 65.0,
              "upper": null
            },
            "groups": [
              {
                "group_name": "Erlotinib",
                "count": null,
                "percentage": 20.9
              },
              {
                "group_name": "GP",
                "count": null,
                "percentage": 20.6
              }
            ]
          }
        ],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "Erlotinib",
                "count": null,
                "percentage": 14.7
              },
              {
                "group_name": "GP",
                "count": null,
                "percentage": 14.4
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "Erlotinib",
                "count": null,
                "percentage": 78.9
              },
              {
                "group_name": "GP",
                "count": null,
                "percentage": 79.8
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 2.0,
              "upper": 2.0
            },
            "groups": [
              {
                "group_name": "Erlotinib",
                "count": null,
                "percentage": 6.4
              },
              {
                "group_name": "GP",
                "count": null,
                "percentage": 5.8
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "erlotinib": {
          "gp": 1.1035691213882313
        },
        "gp": {
          "erlotinib": 0.9061507617593115
        }
      },
      "min_hazard_ratio": 0.9061507617593115
    },
    {
      "identifier": "EORTC22881",
      "pubmed": "25500422",
      "registration": "NCT02295033",
      "publication_date": "2014-12-09 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 5318,
      "weibull_by_arm": {
        "boost": {
          "scale": 397.01476089683257,
          "shape": 1.336348141894921
        },
        "no_boost": {
          "scale": 420.60688671388675,
          "shape": 1.2920007431912623
        }
      },
      "weibull_max_diff": 0.9528372591853231,
      "time_scale": "Months",
      "title": "Randomized Boost Versus no Boost Irradiation of Early Breast Cancer",
      "condition_list": [
        "Breast Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "boost": {
          "no_boost": 0.9605605591312459
        },
        "no_boost": {
          "boost": 1.0410587760384664
        }
      },
      "min_hazard_ratio": 0.9605605591312459
    },
    {
      "identifier": "Eribulin",
      "pubmed": "25605862",
      "registration": "NCT00337103",
      "publication_date": "2015-01-20 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 1102,
      "weibull_by_arm": {
        "capecitabine": {
          "scale": 21.069890405361402,
          "shape": 1.2135654945636845
        },
        "eribulin": {
          "scale": 23.588702180992293,
          "shape": 1.2968709553881437
        }
      },
      "weibull_max_diff": 0.8760580731583885,
      "time_scale": "Months",
      "title": "E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes",
      "condition_list": [
        "Metastatic Breast Cancer"
      ],
      "data_index": {
        "age": [],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "Eribulin",
                "count": 250,
                "percentage": 45.1
              },
              {
                "group_name": "Capecitabine",
                "count": 230,
                "percentage": 42.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "Eribulin",
                "count": 293,
                "percentage": 52.9
              },
              {
                "group_name": "Capecitabine",
                "count": 301,
                "percentage": 54.9
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 2.0,
              "upper": 2.0
            },
            "groups": [
              {
                "group_name": "Eribulin",
                "count": 11,
                "percentage": 2.0
              },
              {
                "group_name": "Capecitabine",
                "count": 16,
                "percentage": 2.9
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 3.0,
              "upper": 3.0
            },
            "groups": [
              {
                "group_name": "Eribulin",
                "count": 0,
                "percentage": 0.0
              },
              {
                "group_name": "Capecitabine",
                "count": 1,
                "percentage": 0.2
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "capecitabine": {
          "eribulin": 0.8790988951511122
        },
        "eribulin": {
          "capecitabine": 1.1375284459072221
        }
      },
      "min_hazard_ratio": 0.8790988951511122
    },
    {
      "identifier": "ESPATUE",
      "pubmed": "26527789",
      "registration": null,
      "publication_date": "2015-11-02 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 161,
      "weibull_by_arm": {
        "arma": {
          "scale": 42.63029822703371,
          "shape": 0.75447579027498
        },
        "armb": {
          "scale": 45.18755356550319,
          "shape": 0.7717196619858958
        }
      },
      "weibull_max_diff": 0.9332229062764944,
      "time_scale": "Months",
      "title": null,
      "condition_list": null,
      "data_index": null,
      "hazard_ratios": {
        "arma": {
          "armb": 0.9649004235484337
        },
        "armb": {
          "arma": 1.0363763716907564
        }
      },
      "min_hazard_ratio": 0.9649004235484337
    },
    {
      "identifier": "ExteNET",
      "pubmed": "26874901",
      "registration": "NCT00878709",
      "publication_date": "2016-02-10 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 2840,
      "weibull_by_arm": {
        "neratinib": {
          "scale": 124.71081130372303,
          "shape": 1.65406868523593
        },
        "placebo": {
          "scale": 204.61144266413515,
          "shape": 1.11204355048102
        }
      },
      "weibull_max_diff": 0.6790144719252794,
      "time_scale": "Unknown",
      "title": "Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer",
      "condition_list": [
        "Breast Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "neratinib": {
          "placebo": 1.466712701178002
        },
        "placebo": {
          "neratinib": 0.6817967821488435
        }
      },
      "min_hazard_ratio": 0.6817967821488435
    },
    {
      "identifier": "FALCON",
      "pubmed": "27908454",
      "registration": "NCT01602380",
      "publication_date": "2016-11-28 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 462,
      "weibull_by_arm": {
        "anastrazole": {
          "scale": 19.55264292503393,
          "shape": 1.2425679568670494
        },
        "fulvestrant": {
          "scale": 24.20991852828077,
          "shape": 1.1879373754721134
        }
      },
      "weibull_max_diff": 0.8186593609943909,
      "time_scale": "Unknown",
      "title": "A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.",
      "condition_list": [
        "Hormone Receptor Positive Breast Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "anastrazole": {
          "fulvestrant": 0.7855328865547712
        },
        "fulvestrant": {
          "anastrazole": 1.2730211772365754
        }
      },
      "min_hazard_ratio": 0.7855328865547712
    },
    {
      "identifier": "FFCD2001",
      "pubmed": "26487578",
      "registration": "NCT00303771",
      "publication_date": "2015-10-20 00:00:00",
      "arms": 2,
      "disease": "colorectal_cancer",
      "subjects": 282,
      "weibull_by_arm": {
        "fu": {
          "scale": 19.233161956658602,
          "shape": 1.1614016254791462
        },
        "iri": {
          "scale": 19.36507543282855,
          "shape": 1.0678563312677158
        }
      },
      "weibull_max_diff": 0.9794053013160864,
      "time_scale": "Months",
      "title": "Combination Chemotherapy as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery",
      "condition_list": [
        "Colorectal Cancer"
      ],
      "data_index": {
        "age": [],
        "ecog": []
      },
      "hazard_ratios": {
        "fu": {
          "iri": 0.9835943335209187
        },
        "iri": {
          "fu": 1.0166793015372049
        }
      },
      "min_hazard_ratio": 0.9835943335209187
    },
    {
      "identifier": "Figitumumab",
      "pubmed": "25395283",
      "registration": "NCT00673049",
      "publication_date": "2014-11-13 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 583,
      "weibull_by_arm": {
        "control": {
          "scale": 9.650897389371242,
          "shape": 1.2524434806700862
        },
        "figitumumab": {
          "scale": 8.869073899805516,
          "shape": 1.0330372658452724
        }
      },
      "weibull_max_diff": 0.8636101672673369,
      "time_scale": "Months",
      "title": "Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer",
      "condition_list": [
        "Carcinoma, Large Cell",
        "Carcinoma, Non-Small-Cell Lung",
        "Carcinoma, Squamous Cell",
        "Carcinoma, Adenosquamous Cell"
      ],
      "data_index": {
        "age": [],
        "ecog": [
          {
            "value_range": {
              "relation": "-",
              "lower": 0.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "Figitumumab arm",
                "count": 237,
                "percentage": 81.0
              },
              {
                "group_name": "Control arm",
                "count": 236,
                "percentage": 82.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 2.0,
              "upper": 2.0
            },
            "groups": [
              {
                "group_name": "Figitumumab arm",
                "count": 56,
                "percentage": 19.0
              },
              {
                "group_name": "Control arm",
                "count": 54,
                "percentage": 19.0
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "control": {
          "figitumumab": 1.0703571498167341
        },
        "figitumumab": {
          "control": 0.934267594859547
        }
      },
      "min_hazard_ratio": 0.934267594859547
    },
    {
      "identifier": "Figitumumab2",
      "pubmed": "24888810",
      "registration": "NCT00596830",
      "publication_date": "2014-06-02 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 681,
      "weibull_by_arm": {
        "control": {
          "scale": 6.225708286482188,
          "shape": 1.4067718967349858
        },
        "figitumumab": {
          "scale": 5.8483113283756465,
          "shape": 1.5540498273238157
        }
      },
      "weibull_max_diff": 0.9628638306090126,
      "time_scale": "Months",
      "title": "Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology",
      "condition_list": [
        "Carcinoma, Squamous Cell",
        "Carcinoma, Adenosquamous",
        "Carcinoma, Large Cell",
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "data_index": {
        "age": [],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "Figitumumab Arm",
                "count": 113,
                "percentage": 33.0
              },
              {
                "group_name": "Control Arm",
                "count": 115,
                "percentage": 34.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "Figitumumab Arm",
                "count": 226,
                "percentage": 66.0
              },
              {
                "group_name": "Control Arm",
                "count": 217,
                "percentage": 64.0
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "control": {
          "figitumumab": 1.0956415246272873
        },
        "figitumumab": {
          "control": 0.9127072838355389
        }
      },
      "min_hazard_ratio": 0.9127072838355389
    },
    {
      "identifier": "FIRE3",
      "pubmed": "25088940",
      "registration": "NCT00433927",
      "publication_date": "2014-08-01 00:00:00",
      "arms": 2,
      "disease": "colorectal_cancer",
      "subjects": 592,
      "weibull_by_arm": {
        "folfiri_bevacizumab": {
          "scale": 32.66381953238477,
          "shape": 1.6069900929785057
        },
        "folfiri_cetuximab": {
          "scale": 39.76809916080087,
          "shape": 1.4301996947965403
        }
      },
      "weibull_max_diff": 0.8448431910894793,
      "time_scale": "Months",
      "title": "5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)",
      "condition_list": [
        "Neoplasm Metastasis",
        "Colorectal Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "folfiri_bevacizumab": {
          "folfiri_cetuximab": 0.7585764851431736
        },
        "folfiri_cetuximab": {
          "folfiri_bevacizumab": 1.3182586325639398
        }
      },
      "min_hazard_ratio": 0.7585764851431736
    },
    {
      "identifier": "GECESTRO-APBI",
      "pubmed": "26494415",
      "registration": "NCT00402519",
      "publication_date": "2015-10-20 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 1184,
      "weibull_by_arm": {
        "apbi": {
          "scale": 543.3106442965797,
          "shape": 1.3358636609340564
        },
        "wbi": {
          "scale": 650.6008862349162,
          "shape": 1.2010845289110679
        }
      },
      "weibull_max_diff": 0.861200870617196,
      "time_scale": "Months",
      "title": "APBI Versus EBRT Therapy After Breast Conserving Surgery for Low-risk Breast Cancer",
      "condition_list": [
        "Breast Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "apbi": {
          "wbi": 1.0888897195309188
        },
        "wbi": {
          "apbi": 0.918366646376998
        }
      },
      "min_hazard_ratio": 0.918366646376998
    },
    {
      "identifier": "GEICAM2003",
      "pubmed": "26416999",
      "registration": "NCT00129935",
      "publication_date": "2015-09-28 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 1384,
      "weibull_by_arm": {
        "ec_t": {
          "scale": 277.2111046153077,
          "shape": 1.2759933044881666
        },
        "et_x": {
          "scale": 237.0403731698626,
          "shape": 1.2009815421995014
        }
      },
      "weibull_max_diff": 0.8398858211574513,
      "time_scale": "Months",
      "title": "EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer",
      "condition_list": [
        "Breast Cancer"
      ],
      "data_index": {
        "age": [],
        "ecog": []
      },
      "hazard_ratios": {
        "ec_t": {
          "et_x": 1.324632628762925
        },
        "et_x": {
          "ec_t": 0.754926292985777
        }
      },
      "min_hazard_ratio": 0.754926292985777
    },
    {
      "identifier": "GETUG12",
      "pubmed": "26028518",
      "registration": "NCT00055731",
      "publication_date": "2015-05-29 00:00:00",
      "arms": 2,
      "disease": "prostate_cancer",
      "subjects": 413,
      "weibull_by_arm": {
        "adt": {
          "scale": 10.439729775941895,
          "shape": 1.5726265908350006
        },
        "adt_de": {
          "scale": 13.35060998582977,
          "shape": 1.4347578549333835
        }
      },
      "weibull_max_diff": 0.7996761963241956,
      "time_scale": "Unknown",
      "title": "Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse",
      "condition_list": [
        "Prostate Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "adt": {
          "adt_de": 0.7323763698052258
        },
        "adt_de": {
          "adt": 1.3654181664353102
        }
      },
      "min_hazard_ratio": 0.7323763698052258
    },
    {
      "identifier": "GETUG16",
      "pubmed": "27160475",
      "registration": "NCT00423475",
      "publication_date": "2016-05-06 00:00:00",
      "arms": 2,
      "disease": "prostate_cancer",
      "subjects": 730,
      "weibull_by_arm": {
        "rt": {
          "scale": 130.76536144067322,
          "shape": 1.0129780912525321
        },
        "rt_goserelin": {
          "scale": 171.0100522508693,
          "shape": 1.4227398473731614
        }
      },
      "weibull_max_diff": 0.6889928800366703,
      "time_scale": "Unknown",
      "title": "Radiation Therapy With or Without Goserelin in Treating Patients Who Have Undergone Surgery for Recurrent or Refractory Prostate Cancer",
      "condition_list": [
        "Prostate Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "rt": {
          "rt_goserelin": 0.5046918978116813
        },
        "rt_goserelin": {
          "rt": 1.9814068827654054
        }
      },
      "min_hazard_ratio": 0.5046918978116813
    },
    {
      "identifier": "GIM",
      "pubmed": "26720025",
      "registration": "NCT00311636",
      "publication_date": "2015-12-22 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 281,
      "weibull_by_arm": {
        "control": {
          "scale": 29.788827248678626,
          "shape": 0.9801912270762765
        },
        "lhrha": {
          "scale": 25.295621651758303,
          "shape": 0.9786535086214679
        }
      },
      "weibull_max_diff": 0.8486659778756654,
      "time_scale": "Unknown",
      "title": "Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery",
      "condition_list": [
        "Breast Cancer"
      ],
      "data_index": {
        "age": [
          {
            "value_range": {
              "relation": "<",
              "lower": null,
              "upper": 30.0
            },
            "groups": [
              {
                "group_name": "Control Group",
                "count": 5,
                "percentage": 3.8
              },
              {
                "group_name": "LHRHa Group",
                "count": 8,
                "percentage": 5.4
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 30.0,
              "upper": 34.0
            },
            "groups": [
              {
                "group_name": "Control Group",
                "count": 23,
                "percentage": 17.3
              },
              {
                "group_name": "LHRHa Group",
                "count": 23,
                "percentage": 15.5
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 35.0,
              "upper": 39.0
            },
            "groups": [
              {
                "group_name": "Control Group",
                "count": 45,
                "percentage": 33.8
              },
              {
                "group_name": "LHRHa Group",
                "count": 46,
                "percentage": 31.1
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 40.0,
              "upper": 44.0
            },
            "groups": [
              {
                "group_name": "Control Group",
                "count": 57,
                "percentage": 42.9
              },
              {
                "group_name": "LHRHa Group",
                "count": 66,
                "percentage": 44.6
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 45.0,
              "upper": 49.0
            },
            "groups": [
              {
                "group_name": "Control Group",
                "count": 3,
                "percentage": 2.3
              },
              {
                "group_name": "LHRHa Group",
                "count": 5,
                "percentage": 3.4
              }
            ]
          }
        ],
        "ecog": []
      },
      "hazard_ratios": {
        "control": {
          "lhrha": 1.177226473806574
        },
        "lhrha": {
          "control": 0.8494542233377487
        }
      },
      "min_hazard_ratio": 0.8494542233377487
    },
    {
      "identifier": "GIM2",
      "pubmed": "25740286",
      "registration": "NCT00433420",
      "publication_date": "2015-03-02 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 2003,
      "weibull_by_arm": {
        "q2": {
          "scale": 226.59765867372897,
          "shape": 1.2333739186947725
        },
        "q3": {
          "scale": 209.9227673268272,
          "shape": 1.0661151259531425
        }
      },
      "weibull_max_diff": 0.8842131803544266,
      "time_scale": "Months",
      "title": "Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer",
      "condition_list": [
        "Breast Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "q2": {
          "q3": 1.3041458598962865
        },
        "q3": {
          "q2": 0.7667853962895883
        }
      },
      "min_hazard_ratio": 0.7667853962895883
    },
    {
      "identifier": "HYPRO",
      "pubmed": "27339116",
      "registration": "ISRCTN85138529",
      "publication_date": "2016-06-20 00:00:00",
      "arms": 2,
      "disease": "prostate_cancer",
      "subjects": 804,
      "weibull_by_arm": {
        "conventional_fractionation": null,
        "hypofractionation": {
          "scale": 180.35369942861834,
          "shape": 1.2836717082921536
        }
      },
      "weibull_max_diff": null,
      "time_scale": "Months",
      "title": null,
      "condition_list": null,
      "data_index": null,
      "hazard_ratios": {
        "conventional_fractionation": {
          "hypofractionation": 0.9781318402384043
        },
        "hypofractionation": {
          "conventional_fractionation": 1.0223570676896334
        }
      },
      "min_hazard_ratio": 0.9781318402384043
    },
    {
      "identifier": "IBCSG2200",
      "pubmed": "27325862",
      "registration": "NCT00022516",
      "publication_date": "2016-06-20 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 1081,
      "weibull_by_arm": {
        "cm_maintenance": {
          "scale": 31.758315851180374,
          "shape": 0.8054851670547456
        },
        "no_cm": {
          "scale": 24.648815614866585,
          "shape": 0.813038699710925
        }
      },
      "weibull_max_diff": 0.7794253335283706,
      "time_scale": "Unknown",
      "title": "Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer",
      "condition_list": [
        "Breast Cancer"
      ],
      "data_index": {
        "age": [],
        "ecog": []
      },
      "hazard_ratios": {
        "cm_maintenance": {
          "no_cm": 1.2109582952493951
        },
        "no_cm": {
          "cm_maintenance": 0.825792270405193
        }
      },
      "min_hazard_ratio": 0.825792270405193
    },
    {
      "identifier": "IMELDA",
      "pubmed": "25273343",
      "registration": "NCT00929240",
      "publication_date": "2014-09-28 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 185,
      "weibull_by_arm": {
        "bevacizumab": {
          "scale": 33.35383954238565,
          "shape": 1.2234032385478497
        },
        "bevacizumab_capecitabine": {
          "scale": 47.32250737809721,
          "shape": 1.6796206364922583
        }
      },
      "weibull_max_diff": 0.6497379659377023,
      "time_scale": "Months",
      "title": "A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer",
      "condition_list": [
        "Breast Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "bevacizumab": {
          "bevacizumab_capecitabine": 0.5136499224137542
        },
        "bevacizumab_capecitabine": {
          "bevacizumab": 1.9468512626280168
        }
      },
      "min_hazard_ratio": 0.5136499224137542
    },
    {
      "identifier": "IMPRESS",
      "pubmed": "26159065",
      "registration": "NCT01544179",
      "publication_date": "2015-07-07 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 265,
      "weibull_by_arm": {
        "gefitinib": {
          "scale": 6.847332348593456,
          "shape": 1.69193225157763
        },
        "placebo": {
          "scale": 6.00344184003537,
          "shape": 1.6296956339859818
        }
      },
      "weibull_max_diff": 0.8695331110127221,
      "time_scale": "Unknown",
      "title": "A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone",
      "condition_list": [
        "Non-Small Cell Lung Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "gefitinib": {
          "placebo": 1.218912513332584
        },
        "placebo": {
          "gefitinib": 0.8204034244147159
        }
      },
      "min_hazard_ratio": 0.8204034244147159
    },
    {
      "identifier": "Iniparib",
      "pubmed": "25349301",
      "registration": "NCT00938652",
      "publication_date": "2014-10-27 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 519,
      "weibull_by_arm": {
        "gc": {
          "scale": 13.99942298423129,
          "shape": 1.3962938571310528
        },
        "gci": {
          "scale": 15.170845061283135,
          "shape": 1.4810074090118748
        }
      },
      "weibull_max_diff": 0.9090330840357158,
      "time_scale": "Months",
      "title": "A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer",
      "condition_list": [
        "Breast Cancer"
      ],
      "data_index": {
        "age": [
          {
            "value_range": {
              "relation": "<",
              "lower": null,
              "upper": 50.0
            },
            "groups": [
              {
                "group_name": "Gemcitabine and Carboplatin",
                "count": 91,
                "percentage": 35.0
              },
              {
                "group_name": "Gemcitabine, Carboplatin, and Iniparib",
                "count": 91,
                "percentage": 35.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "≥",
              "lower": 50.0,
              "upper": null
            },
            "groups": [
              {
                "group_name": "Gemcitabine and Carboplatin",
                "count": 167,
                "percentage": 65.0
              },
              {
                "group_name": "Gemcitabine, Carboplatin, and Iniparib",
                "count": 170,
                "percentage": 65.0
              }
            ]
          }
        ],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "Gemcitabine and Carboplatin",
                "count": 137,
                "percentage": 53.0
              },
              {
                "group_name": "Gemcitabine, Carboplatin, and Iniparib",
                "count": 148,
                "percentage": 57.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "Gemcitabine and Carboplatin",
                "count": 117,
                "percentage": 45.0
              },
              {
                "group_name": "Gemcitabine, Carboplatin, and Iniparib",
                "count": 108,
                "percentage": 41.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 2.0,
              "upper": 2.0
            },
            "groups": [
              {
                "group_name": "Gemcitabine and Carboplatin",
                "count": 4,
                "percentage": 2.0
              },
              {
                "group_name": "Gemcitabine, Carboplatin, and Iniparib",
                "count": 5,
                "percentage": 2.0
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "gc": {
          "gci": 0.8681086286088634
        },
        "gci": {
          "gc": 1.1519295708447126
        }
      },
      "min_hazard_ratio": 0.8681086286088634
    },
    {
      "identifier": "INSPIRE",
      "pubmed": "25701171",
      "registration": "NCT00982111",
      "publication_date": "2015-02-18 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 633,
      "weibull_by_arm": {
        "ct": {
          "scale": 7.433962278462784,
          "shape": 1.224841381745874
        },
        "necitumumab_ct": {
          "scale": 8.064026394587762,
          "shape": 1.188044500521541
        }
      },
      "weibull_max_diff": 0.9304509199606321,
      "time_scale": "Months",
      "title": "First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin",
      "condition_list": [
        "Non Small Cell Lung Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "ct": {
          "necitumumab_ct": 0.9220894743843224
        },
        "necitumumab_ct": {
          "ct": 1.0844934551147527
        }
      },
      "min_hazard_ratio": 0.9220894743843224
    },
    {
      "identifier": "INT0142",
      "pubmed": "25349302",
      "registration": "NR",
      "publication_date": "2014-10-27 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 337,
      "weibull_by_arm": {
        "tamoxifen": {
          "scale": 1415.5005505518843,
          "shape": 0.720802575119548
        },
        "tamoxifen_ofs": {
          "scale": 1191.9015167820728,
          "shape": 0.849380809717511
        }
      },
      "weibull_max_diff": 0.9094089942146336,
      "time_scale": "Months",
      "title": null,
      "condition_list": null,
      "data_index": {
        "age": [
          {
            "value_range": {
              "relation": "-",
              "lower": 26.0,
              "upper": 40.0
            },
            "groups": [
              {
                "group_name": "Tamoxifen Alone",
                "count": 22,
                "percentage": 13.2
              },
              {
                "group_name": "Tamoxifen + OFS",
                "count": 36,
                "percentage": 21.2
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 41.0,
              "upper": 50.0
            },
            "groups": [
              {
                "group_name": "Tamoxifen Alone",
                "count": 117,
                "percentage": 70.1
              },
              {
                "group_name": "Tamoxifen + OFS",
                "count": 111,
                "percentage": 65.3
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 51.0,
              "upper": 55.0
            },
            "groups": [
              {
                "group_name": "Tamoxifen Alone",
                "count": 28,
                "percentage": 16.8
              },
              {
                "group_name": "Tamoxifen + OFS",
                "count": 23,
                "percentage": 13.5
              }
            ]
          }
        ],
        "ecog": []
      },
      "hazard_ratios": {
        "tamoxifen": {
          "tamoxifen_ofs": 0.8314175799185108
        },
        "tamoxifen_ofs": {
          "tamoxifen": 1.202765041482539
        }
      },
      "min_hazard_ratio": 0.8314175799185108
    },
    {
      "identifier": "ITACa",
      "pubmed": "25735317",
      "registration": "NCT01878422",
      "publication_date": "2015-03-03 00:00:00",
      "arms": 2,
      "disease": "colorectal_cancer",
      "subjects": 370,
      "weibull_by_arm": {
        "ct": {
          "scale": 28.70755197337413,
          "shape": 1.5630067953277014
        },
        "ct_b": {
          "scale": 26.867127080128814,
          "shape": 1.221306434995404
        }
      },
      "weibull_max_diff": 0.8764605539391427,
      "time_scale": "Months",
      "title": "Sequential Treatment Strategy for Metastatic Colorectal Cancer",
      "condition_list": [
        "Metastatic Colorectal Cancer"
      ],
      "data_index": {
        "age": [],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "CT + B",
                "count": 144,
                "percentage": 81.8
              },
              {
                "group_name": "CT",
                "count": 154,
                "percentage": 79.4
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 1.0,
              "upper": 2.0
            },
            "groups": [
              {
                "group_name": "CT + B",
                "count": 32,
                "percentage": 18.2
              },
              {
                "group_name": "CT",
                "count": 40,
                "percentage": 20.6
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "ct": {
          "ct_b": 1.1026559391285584
        },
        "ct_b": {
          "ct": 0.9069012050942303
        }
      },
      "min_hazard_ratio": 0.9069012050942303
    },
    {
      "identifier": "JCOG0509",
      "pubmed": "24638015",
      "registration": "UMIN000000720",
      "publication_date": "2014-03-17 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 284,
      "weibull_by_arm": {
        "amrubicin_cisplatin": {
          "scale": 6.449946186603248,
          "shape": 1.4623169869974113
        },
        "irinotecan_cisplatin": {
          "scale": 7.921788268982463,
          "shape": 1.5187813353867672
        }
      },
      "weibull_max_diff": 0.8066517238495836,
      "time_scale": "Months",
      "title": null,
      "condition_list": null,
      "data_index": {
        "age": [],
        "ecog": []
      },
      "hazard_ratios": {
        "amrubicin_cisplatin": {
          "irinotecan_cisplatin": 0.6958584967026972
        },
        "irinotecan_cisplatin": {
          "amrubicin_cisplatin": 1.437073779710196
        }
      },
      "min_hazard_ratio": 0.6958584967026972
    },
    {
      "identifier": "JCOG0605",
      "pubmed": "27312053",
      "registration": "UMIN000000828",
      "publication_date": "2016-06-13 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 180,
      "weibull_by_arm": {
        "combination_chemotherapy": {
          "scale": 23.84023030928263,
          "shape": 1.6852274295541605
        },
        "topotecan": {
          "scale": 17.664740291819594,
          "shape": 1.32528791906166
        }
      },
      "weibull_max_diff": 0.6984640124116194,
      "time_scale": "Months",
      "title": null,
      "condition_list": null,
      "data_index": null,
      "hazard_ratios": {
        "combination_chemotherapy": {
          "topotecan": 1.5409470824726297
        },
        "topotecan": {
          "combination_chemotherapy": 0.6489515515324401
        }
      },
      "min_hazard_ratio": 0.6489515515324401
    },
    {
      "identifier": "JFMC33-0502",
      "pubmed": "26347106",
      "registration": "UMIN-CTR C000000245",
      "publication_date": "2015-09-07 00:00:00",
      "arms": 2,
      "disease": "colorectal_cancer",
      "subjects": 1060,
      "weibull_by_arm": {
        "control": {
          "scale": 224.59988816239252,
          "shape": 1.4326402254403396
        },
        "study": {
          "scale": 182.95806667320437,
          "shape": 1.6016374957974904
        }
      },
      "weibull_max_diff": 0.8368842255249666,
      "time_scale": "Months",
      "title": null,
      "condition_list": null,
      "data_index": {
        "age": [
          {
            "value_range": {
              "relation": "≤",
              "lower": null,
              "upper": 50.0
            },
            "groups": [
              {
                "group_name": "Control",
                "count": 51,
                "percentage": 9.6
              },
              {
                "group_name": "Study",
                "count": 51,
                "percentage": 9.5
              },
              {
                "group_name": "Total",
                "count": 102,
                "percentage": 9.5
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 51.0,
              "upper": 60.0
            },
            "groups": [
              {
                "group_name": "Control",
                "count": 140,
                "percentage": 26.2
              },
              {
                "group_name": "Study",
                "count": 154,
                "percentage": 28.7
              },
              {
                "group_name": "Total",
                "count": 294,
                "percentage": 27.5
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 61.0,
              "upper": 70.0
            },
            "groups": [
              {
                "group_name": "Control",
                "count": 231,
                "percentage": 43.3
              },
              {
                "group_name": "Study",
                "count": 228,
                "percentage": 42.5
              },
              {
                "group_name": "Total",
                "count": 459,
                "percentage": 42.9
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 71.0,
              "upper": 80.0
            },
            "groups": [
              {
                "group_name": "Control",
                "count": 112,
                "percentage": 21.0
              },
              {
                "group_name": "Study",
                "count": 104,
                "percentage": 19.4
              },
              {
                "group_name": "Total",
                "count": 216,
                "percentage": 20.2
              }
            ]
          }
        ],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "Control",
                "count": 503,
                "percentage": 94.2
              },
              {
                "group_name": "Study",
                "count": 517,
                "percentage": 96.3
              },
              {
                "group_name": "Total",
                "count": 1020,
                "percentage": 95.2
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "Control",
                "count": 31,
                "percentage": 5.8
              },
              {
                "group_name": "Study",
                "count": 20,
                "percentage": 3.7
              },
              {
                "group_name": "Total",
                "count": 51,
                "percentage": 4.8
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "control": {
          "study": 1.130290677559507
        },
        "study": {
          "control": 0.8847281675888656
        }
      },
      "min_hazard_ratio": 0.8847281675888656
    },
    {
      "identifier": "KEYNOTE024",
      "pubmed": "27718847",
      "registration": "NCT02142738 ",
      "publication_date": "2016-10-09 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 305,
      "weibull_by_arm": {
        "chemotherapy": {
          "scale": 6.781443964730418,
          "shape": 1.352877992037303
        },
        "pembrolizumab": {
          "scale": 14.863316613256066,
          "shape": 0.8712172320115487
        }
      },
      "weibull_max_diff": 0.5299730967914621,
      "time_scale": "Months",
      "title": null,
      "condition_list": null,
      "data_index": {
        "age": [],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "Pembrolizumab Group",
                "count": 54,
                "percentage": 35.1
              },
              {
                "group_name": "Chemotherapy Group",
                "count": 53,
                "percentage": 35.1
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "Pembrolizumab Group",
                "count": 99,
                "percentage": 64.3
              },
              {
                "group_name": "Chemotherapy Group",
                "count": 98,
                "percentage": 64.9
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "chemotherapy": {
          "pembrolizumab": 0.4874003368488659
        },
        "pembrolizumab": {
          "chemotherapy": 2.0517014954589206
        }
      },
      "min_hazard_ratio": 0.4874003368488659
    },
    {
      "identifier": "LEA",
      "pubmed": "25691671",
      "registration": "NCT00545077",
      "publication_date": "2015-02-17 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 374,
      "weibull_by_arm": {
        "et": {
          "scale": 61.47421866641948,
          "shape": 1.8982996749418506
        },
        "et_b": {
          "scale": 62.64677691122132,
          "shape": 1.6896586927649886
        }
      },
      "weibull_max_diff": 0.995065533189882,
      "time_scale": "Months",
      "title": "Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women",
      "condition_list": [
        "Breast Cancer"
      ],
      "data_index": {
        "age": [
          {
            "value_range": {
              "relation": "<",
              "lower": null,
              "upper": 40.0
            },
            "groups": [
              {
                "group_name": "ET",
                "count": 1,
                "percentage": 0.5
              },
              {
                "group_name": "ET-B",
                "count": 2,
                "percentage": 1.1
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 40.0,
              "upper": 64.0
            },
            "groups": [
              {
                "group_name": "ET",
                "count": 83,
                "percentage": 45.2
              },
              {
                "group_name": "ET-B",
                "count": 99,
                "percentage": 52.1
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 65.0,
              "upper": 69.0
            },
            "groups": [
              {
                "group_name": "ET",
                "count": 35,
                "percentage": 19.0
              },
              {
                "group_name": "ET-B",
                "count": 34,
                "percentage": 17.9
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 70.0,
              "upper": 80.0
            },
            "groups": [
              {
                "group_name": "ET",
                "count": 58,
                "percentage": 31.5
              },
              {
                "group_name": "ET-B",
                "count": 47,
                "percentage": 24.7
              }
            ]
          },
          {
            "value_range": {
              "relation": ">",
              "lower": 80.0,
              "upper": null
            },
            "groups": [
              {
                "group_name": "ET",
                "count": 7,
                "percentage": 3.8
              },
              {
                "group_name": "ET-B",
                "count": 8,
                "percentage": 4.2
              }
            ]
          }
        ],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "ET",
                "count": 131,
                "percentage": 71.2
              },
              {
                "group_name": "ET-B",
                "count": 139,
                "percentage": 73.2
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "ET",
                "count": 53,
                "percentage": 28.8
              },
              {
                "group_name": "ET-B",
                "count": 51,
                "percentage": 26.8
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "et": {
          "et_b": 1.1356278640866047
        },
        "et_b": {
          "et": 0.8805701512126145
        }
      },
      "min_hazard_ratio": 0.8805701512126145
    },
    {
      "identifier": "LUMELung1",
      "pubmed": "24411639",
      "registration": "NCT00805194",
      "publication_date": "2014-01-09 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 1134,
      "weibull_by_arm": {
        "docetaxel_nintedanib": {
          "scale": 4.574611149069907,
          "shape": 1.5060049905639479
        },
        "docetaxel_placebo": {
          "scale": 3.8117086616542792,
          "shape": 1.4391960304255043
        }
      },
      "weibull_max_diff": 0.8238708295895204,
      "time_scale": "Months",
      "title": "LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer",
      "condition_list": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "data_index": null,
      "hazard_ratios": {
        "docetaxel_nintedanib": {
          "docetaxel_placebo": 1.2661784701565484
        },
        "docetaxel_placebo": {
          "docetaxel_nintedanib": 0.7897780791331587
        }
      },
      "min_hazard_ratio": 0.7897780791331587
    },
    {
      "identifier": "LUXBreast1",
      "pubmed": "26822398",
      "registration": "NCT01125566",
      "publication_date": "2016-01-25 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 508,
      "weibull_by_arm": {
        "afatinib": {
          "scale": 27.11358985043573,
          "shape": 1.3670383098703451
        },
        "trastuzumab": {
          "scale": 35.18559149904294,
          "shape": 1.4428101932288098
        }
      },
      "weibull_max_diff": 0.7598138953166015,
      "time_scale": "Months",
      "title": "LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment",
      "condition_list": [
        "Breast Neoplasms"
      ],
      "data_index": null,
      "hazard_ratios": {
        "afatinib": {
          "trastuzumab": 0.6788545873249003
        },
        "trastuzumab": {
          "afatinib": 1.4730695183789029
        }
      },
      "min_hazard_ratio": 0.6788545873249003
    },
    {
      "identifier": "LUXLung3-6",
      "pubmed": "25589191",
      "registration": "NCT00949650/NCT01121393",
      "publication_date": "2015-01-12 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 345,
      "weibull_by_arm": {
        "afatinib": {
          "scale": 39.07881160906308,
          "shape": 1.3792886182259843
        },
        "ct": {
          "scale": 35.44322588245273,
          "shape": 1.5337595045849466
        }
      },
      "weibull_max_diff": 0.9315681149958189,
      "time_scale": "Months",
      "title": null,
      "condition_list": null,
      "data_index": null,
      "hazard_ratios": {
        "afatinib": {
          "ct": 1.140204067580736
        },
        "ct": {
          "afatinib": 0.8770359871823482
        }
      },
      "min_hazard_ratio": 0.8770359871823482
    },
    {
      "identifier": "LUXLung8",
      "pubmed": "26156651",
      "registration": "NCT01523587",
      "publication_date": "2015-07-06 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 795,
      "weibull_by_arm": {
        "afatinib": {
          "scale": 12.069294817227805,
          "shape": 1.140846736918917
        },
        "erlotinib": {
          "scale": 9.97728399224739,
          "shape": 1.2438928518052412
        }
      },
      "weibull_max_diff": 0.8489630026397991,
      "time_scale": "Months",
      "title": "LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy",
      "condition_list": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "data_index": null,
      "hazard_ratios": {
        "afatinib": {
          "erlotinib": 1.2471748390305148
        },
        "erlotinib": {
          "afatinib": 0.8018121988231778
        }
      },
      "min_hazard_ratio": 0.8018121988231778
    },
    {
      "identifier": "MA17R",
      "pubmed": "27264120",
      "registration": "NCT00003140,NCT00754845",
      "publication_date": "2016-06-28 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 1918,
      "weibull_by_arm": {
        "letrozole": {
          "scale": 334.32489869279243,
          "shape": 1.6017319763844164
        },
        "placebo": {
          "scale": 300.7487519033388,
          "shape": 1.7213689049575749
        }
      },
      "weibull_max_diff": 0.9139909236693261,
      "time_scale": "Months",
      "title": null,
      "condition_list": null,
      "data_index": {
        "age": [],
        "ecog": []
      },
      "hazard_ratios": {
        "letrozole": {
          "placebo": 1.0240546638227424
        },
        "placebo": {
          "letrozole": 0.9765103712989817
        }
      },
      "min_hazard_ratio": 0.9765103712989817
    },
    {
      "identifier": "MA31",
      "pubmed": "25779558",
      "registration": "NCT00667251",
      "publication_date": "2015-03-16 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 652,
      "weibull_by_arm": {
        "ltax_l": {
          "scale": 44.33832852714683,
          "shape": 1.3782535501788287
        },
        "ttax_t": {
          "scale": 55.6577970544606,
          "shape": 1.3510174165313507
        }
      },
      "weibull_max_diff": 0.8009060065850866,
      "time_scale": "Months",
      "title": "Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer",
      "condition_list": [
        "Breast Cancer"
      ],
      "data_index": {
        "age": [
          {
            "value_range": {
              "relation": "≤",
              "lower": null,
              "upper": 39.0
            },
            "groups": [
              {
                "group_name": "LTax/L",
                "count": 28,
                "percentage": 9.0
              },
              {
                "group_name": "TTax/T",
                "count": 21,
                "percentage": 6.0
              },
              {
                "group_name": "Total",
                "count": 49,
                "percentage": 8.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 40.0,
              "upper": 49.0
            },
            "groups": [
              {
                "group_name": "LTax/L",
                "count": 71,
                "percentage": 22.0
              },
              {
                "group_name": "TTax/T",
                "count": 102,
                "percentage": 31.0
              },
              {
                "group_name": "Total",
                "count": 173,
                "percentage": 27.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 50.0,
              "upper": 59.0
            },
            "groups": [
              {
                "group_name": "LTax/L",
                "count": 117,
                "percentage": 36.0
              },
              {
                "group_name": "TTax/T",
                "count": 110,
                "percentage": 34.0
              },
              {
                "group_name": "Total",
                "count": 227,
                "percentage": 35.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 60.0,
              "upper": 69.0
            },
            "groups": [
              {
                "group_name": "LTax/L",
                "count": 77,
                "percentage": 24.0
              },
              {
                "group_name": "TTax/T",
                "count": 66,
                "percentage": 20.0
              },
              {
                "group_name": "Total",
                "count": 143,
                "percentage": 22.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "≥",
              "lower": 70.0,
              "upper": null
            },
            "groups": [
              {
                "group_name": "LTax/L",
                "count": 33,
                "percentage": 10.0
              },
              {
                "group_name": "TTax/T",
                "count": 27,
                "percentage": 8.0
              },
              {
                "group_name": "Total",
                "count": 60,
                "percentage": 9.0
              }
            ]
          }
        ],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "LTax/L",
                "count": 196,
                "percentage": 60.0
              },
              {
                "group_name": "TTax/T",
                "count": 204,
                "percentage": 63.0
              },
              {
                "group_name": "Total",
                "count": 400,
                "percentage": 61.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "LTax/L",
                "count": 118,
                "percentage": 36.0
              },
              {
                "group_name": "TTax/T",
                "count": 112,
                "percentage": 34.0
              },
              {
                "group_name": "Total",
                "count": 230,
                "percentage": 35.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 2.0,
              "upper": 2.0
            },
            "groups": [
              {
                "group_name": "LTax/L",
                "count": 12,
                "percentage": 4.0
              },
              {
                "group_name": "TTax/T",
                "count": 10,
                "percentage": 3.0
              },
              {
                "group_name": "Total",
                "count": 22,
                "percentage": 3.0
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "ltax_l": {
          "ttax_t": 0.7454346915035306
        },
        "ttax_t": {
          "ltax_l": 1.3414991432489076
        }
      },
      "min_hazard_ratio": 0.7454346915035306
    },
    {
      "identifier": "MAGRIT",
      "pubmed": "27132212",
      "registration": "NCT00480025",
      "publication_date": "2016-04-27 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 2272,
      "weibull_by_arm": {
        "mage_a3": {
          "scale": 85.21298965008863,
          "shape": 0.7928715840528753
        },
        "placebo": {
          "scale": 87.53474754972187,
          "shape": 0.7925884617958551
        }
      },
      "weibull_max_diff": 0.9736369154913077,
      "time_scale": "Unknown",
      "title": "GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer",
      "condition_list": [
        "Lung Cancer, Non-Small Cell"
      ],
      "data_index": null,
      "hazard_ratios": {
        "mage_a3": {
          "placebo": 0.9826073156800658
        },
        "placebo": {
          "mage_a3": 1.0177005442992215
        }
      },
      "min_hazard_ratio": 0.9826073156800658
    },
    {
      "identifier": "MAINSAIL",
      "pubmed": "25743937",
      "registration": "NCT00988208",
      "publication_date": "2015-03-03 00:00:00",
      "arms": 2,
      "disease": "prostate_cancer",
      "subjects": 1059,
      "weibull_by_arm": {
        "lenolidomide": {
          "scale": 22.4526935068759,
          "shape": 1.7439801865234412
        },
        "placebo": {
          "scale": 26.616526217176588,
          "shape": 1.8739702918097219
        }
      },
      "weibull_max_diff": 0.8313539546419266,
      "time_scale": "Months",
      "title": "Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer",
      "condition_list": [
        "Prostate Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "lenolidomide": {
          "placebo": 0.6576682175665367
        },
        "placebo": {
          "lenolidomide": 1.5205235303906557
        }
      },
      "min_hazard_ratio": 0.6576682175665367
    },
    {
      "identifier": "MAPS",
      "pubmed": "26719230",
      "registration": "NCT00651456",
      "publication_date": "2015-12-21 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 448,
      "weibull_by_arm": {
        "pc": {
          "scale": 24.23011719301944,
          "shape": 1.2884369479476332
        },
        "pcb": {
          "scale": 27.569603366700623,
          "shape": 1.2326556809477507
        }
      },
      "weibull_max_diff": 0.8902573718520987,
      "time_scale": "Months",
      "title": "Mesothelioma Avastin Plus Pemetrexed-cisplatin Study",
      "condition_list": [
        "Mesothelioma"
      ],
      "data_index": null,
      "hazard_ratios": {
        "pc": {
          "pcb": 0.842549616309941
        },
        "pcb": {
          "pc": 1.186873723092575
        }
      },
      "min_hazard_ratio": 0.842549616309941
    },
    {
      "identifier": "MARIANNE",
      "pubmed": "28056202",
      "registration": "NCT01120184",
      "publication_date": "2016-11-07 00:00:00",
      "arms": 3,
      "disease": "breast_cancer",
      "subjects": 1095,
      "weibull_by_arm": {
        "t-dm1": {
          "scale": 23.998505042629578,
          "shape": 0.9254800008420486
        },
        "t-dm1_pertuzumab": {
          "scale": 26.51270633002206,
          "shape": 0.9930213691298805
        },
        "trastuzumab_taxane": {
          "scale": 21.571392461312826,
          "shape": 1.1632994307444589
        }
      },
      "weibull_max_diff": 0.8587901327489724,
      "time_scale": "Unknown",
      "title": "A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)",
      "condition_list": [
        "Breast Cancer"
      ],
      "data_index": {
        "age": [],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "Trastuzumab + Taxane",
                "count": 245,
                "percentage": 67.1
              },
              {
                "group_name": "T-DM1",
                "count": 239,
                "percentage": 65.1
              },
              {
                "group_name": "T-DM1 + Pertuzumab",
                "count": 235,
                "percentage": 64.7
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "Trastuzumab + Taxane",
                "count": 119,
                "percentage": 32.6
              },
              {
                "group_name": "T-DM1",
                "count": 128,
                "percentage": 34.9
              },
              {
                "group_name": "T-DM1 + Pertuzumab",
                "count": 127,
                "percentage": 35.0
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "t-dm1": {
          "t-dm1_pertuzumab": 0.9020659948489711,
          "trastuzumab_taxane": 1.0631036957940558
        },
        "t-dm1_pertuzumab": {
          "t-dm1": 1.1085663418311489,
          "trastuzumab_taxane": 1.178938263579872
        },
        "trastuzumab_taxane": {
          "t-dm1": 0.940642012586625,
          "t-dm1_pertuzumab": 0.8482208364019655
        }
      },
      "min_hazard_ratio": 0.8482208364019655
    },
    {
      "identifier": "MARQUEE",
      "pubmed": "26169611",
      "registration": "NCT01244191",
      "publication_date": "2015-07-13 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 1048,
      "weibull_by_arm": {
        "erlotinib_placebo": {
          "scale": 17.895822582257793,
          "shape": 1.201897828275707
        },
        "erlotinib_tivantinib": {
          "scale": 23.280289720112997,
          "shape": 1.2270267924793543
        }
      },
      "weibull_max_diff": 0.7639255830383987,
      "time_scale": "Months",
      "title": "Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer",
      "condition_list": [
        "Non Squamous, Non-small-cell Lung Cancer"
      ],
      "data_index": {
        "age": [],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "Erlotinib Plus Tivantinib",
                "count": 168,
                "percentage": 31.9
              },
              {
                "group_name": "Erlotinib Plus Placebo",
                "count": 168,
                "percentage": 32.2
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "Erlotinib Plus Tivantinib",
                "count": 357,
                "percentage": 67.9
              },
              {
                "group_name": "Erlotinib Plus Placebo",
                "count": 353,
                "percentage": 67.6
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 2.0,
              "upper": 2.0
            },
            "groups": [
              {
                "group_name": "Erlotinib Plus Tivantinib",
                "count": 1,
                "percentage": 0.2
              },
              {
                "group_name": "Erlotinib Plus Placebo",
                "count": 1,
                "percentage": 0.2
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "erlotinib_placebo": {
          "erlotinib_tivantinib": 0.7363598295019215
        },
        "erlotinib_tivantinib": {
          "erlotinib_placebo": 1.3580317121269454
        }
      },
      "min_hazard_ratio": 0.7363598295019215
    },
    {
      "identifier": "METlung",
      "pubmed": "27937096",
      "registration": "NCT01456325",
      "publication_date": "2016-12-12 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 499,
      "weibull_by_arm": {
        "onaturzumab_erlotinib": {
          "scale": 3.9358677509221347,
          "shape": 1.2552412065139813
        },
        "placebo_erlotinib": {
          "scale": 3.9813460774444134,
          "shape": 1.1288852636684603
        }
      },
      "weibull_max_diff": 0.9790296441006507,
      "time_scale": "Months",
      "title": "A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)",
      "condition_list": [
        "Non-Squamous Non-Small Cell Lung Cancer"
      ],
      "data_index": {
        "age": [],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "Onartuzumab + Erlotinib",
                "count": 93,
                "percentage": 37.0
              },
              {
                "group_name": "Placebo + Erlotinib",
                "count": 78,
                "percentage": 31.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "Onartuzumab + Erlotinib",
                "count": 153,
                "percentage": 61.0
              },
              {
                "group_name": "Placebo + Erlotinib",
                "count": 169,
                "percentage": 68.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 2.0,
              "upper": 2.0
            },
            "groups": [
              {
                "group_name": "Onartuzumab + Erlotinib",
                "count": 4,
                "percentage": 2.0
              },
              {
                "group_name": "Placebo + Erlotinib",
                "count": 1,
                "percentage": 0.5
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "onaturzumab_erlotinib": {
          "placebo_erlotinib": 0.9951102449927552
        },
        "placebo_erlotinib": {
          "onaturzumab_erlotinib": 1.0049137821983538
        }
      },
      "min_hazard_ratio": 0.9951102449927552
    },
    {
      "identifier": "MINDACT",
      "pubmed": "27557300",
      "registration": "NCT00433589",
      "publication_date": "2016-08-25 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 690,
      "weibull_by_arm": {
        "chemotherapy": {
          "scale": 47.66664840069843,
          "shape": 1.0969772682825552
        },
        "no_chemotherapy": {
          "scale": 23.88495482559643,
          "shape": 1.483314428566777
        }
      },
      "weibull_max_diff": 0.5466415287646568,
      "time_scale": "Unknown",
      "title": "Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes",
      "condition_list": [
        "Breast Cancer"
      ],
      "data_index": {
        "age": [
          {
            "value_range": {
              "relation": "<",
              "lower": null,
              "upper": 35.0
            },
            "groups": [
              {
                "group_name": "Low Clinical Risk, Low Genomic Risk",
                "count": 24,
                "percentage": 0.9
              },
              {
                "group_name": "Low Clinical Risk, High Genomic Risk",
                "count": 13,
                "percentage": 2.2
              },
              {
                "group_name": "High Clinical Risk, Low Genomic Risk",
                "count": 20,
                "percentage": 1.3
              },
              {
                "group_name": "High Clinical Risk, High Genomic Risk",
                "count": 65,
                "percentage": 3.6
              },
              {
                "group_name": "All Patients",
                "count": 122,
                "percentage": 1.8
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 35.0,
              "upper": 50.0
            },
            "groups": [
              {
                "group_name": "Low Clinical Risk, Low Genomic Risk",
                "count": 774,
                "percentage": 28.2
              },
              {
                "group_name": "Low Clinical Risk, High Genomic Risk",
                "count": 165,
                "percentage": 27.9
              },
              {
                "group_name": "High Clinical Risk, Low Genomic Risk",
                "count": 514,
                "percentage": 33.2
              },
              {
                "group_name": "High Clinical Risk, High Genomic Risk",
                "count": 651,
                "percentage": 36.0
              },
              {
                "group_name": "All Patients",
                "count": 2104,
                "percentage": 31.4
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 50.0,
              "upper": 70.0
            },
            "groups": [
              {
                "group_name": "Low Clinical Risk, Low Genomic Risk",
                "count": 1928,
                "percentage": 70.2
              },
              {
                "group_name": "Low Clinical Risk, High Genomic Risk",
                "count": 403,
                "percentage": 68.1
              },
              {
                "group_name": "High Clinical Risk, Low Genomic Risk",
                "count": 1000,
                "percentage": 64.5
              },
              {
                "group_name": "High Clinical Risk, High Genomic Risk",
                "count": 1080,
                "percentage": 59.8
              },
              {
                "group_name": "All Patients",
                "count": 4411,
                "percentage": 65.9
              }
            ]
          },
          {
            "value_range": {
              "relation": ">",
              "lower": 70.0,
              "upper": null
            },
            "groups": [
              {
                "group_name": "Low Clinical Risk, Low Genomic Risk",
                "count": 19,
                "percentage": 0.7
              },
              {
                "group_name": "Low Clinical Risk, High Genomic Risk",
                "count": 11,
                "percentage": 1.9
              },
              {
                "group_name": "High Clinical Risk, Low Genomic Risk",
                "count": 16,
                "percentage": 1.0
              },
              {
                "group_name": "High Clinical Risk, High Genomic Risk",
                "count": 10,
                "percentage": 0.6
              },
              {
                "group_name": "All Patients",
                "count": 56,
                "percentage": 0.8
              }
            ]
          }
        ],
        "ecog": []
      },
      "hazard_ratios": {
        "chemotherapy": {
          "no_chemotherapy": 1.1971818464688657
        },
        "no_chemotherapy": {
          "chemotherapy": 0.8352949912743318
        }
      },
      "min_hazard_ratio": 0.8352949912743318
    },
    {
      "identifier": "MIROX",
      "pubmed": "25403578",
      "registration": "NCT00268398",
      "publication_date": "2014-11-17 00:00:00",
      "arms": 2,
      "disease": "colorectal_cancer",
      "subjects": 282,
      "weibull_by_arm": {
        "folfox4": {
          "scale": 52.6730175035074,
          "shape": 0.8598996315093516
        },
        "folfox7_folfiri": {
          "scale": 52.54506435747728,
          "shape": 0.8612718173245202
        }
      },
      "weibull_max_diff": 0.998248452763057,
      "time_scale": "Months",
      "title": "Combination Chemotherapy in Treating Patients With Colorectal Cancer and Resectable Metastases",
      "condition_list": [
        "Colorectal Cancer",
        "Metastatic Cancer",
        "Chemotherapy"
      ],
      "data_index": {
        "age": [],
        "ecog": []
      },
      "hazard_ratios": {
        "folfox4": {
          "folfox7_folfiri": 0.9969235013642661
        },
        "folfox7_folfiri": {
          "folfox4": 1.0030859926880284
        }
      },
      "min_hazard_ratio": 0.9969235013642661
    },
    {
      "identifier": "MONALEESA2",
      "pubmed": "27717303",
      "registration": "NCT01958021",
      "publication_date": "2016-10-08 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 668,
      "weibull_by_arm": {
        "placebo": {
          "scale": 20.290229978468172,
          "shape": 1.2413416601488336
        },
        "ribociclib_letrozole": {
          "scale": 34.13624741433493,
          "shape": 1.172988675955743
        }
      },
      "weibull_max_diff": 0.6047047053753816,
      "time_scale": "Unknown",
      "title": "Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer",
      "condition_list": [
        "Advanced, Metastatic Breast Cancer"
      ],
      "data_index": {
        "age": [],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "Ribociclib Group",
                "count": 205,
                "percentage": 61.4
              },
              {
                "group_name": "Placebo Group",
                "count": 202,
                "percentage": 60.5
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "Ribociclib Group",
                "count": 129,
                "percentage": 38.6
              },
              {
                "group_name": "Placebo Group",
                "count": 132,
                "percentage": 39.5
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "placebo": {
          "ribociclib_letrozole": 0.5589104471819617
        },
        "ribociclib_letrozole": {
          "placebo": 1.7891953980141562
        }
      },
      "min_hazard_ratio": 0.5589104471819617
    },
    {
      "identifier": "MRC-RT01",
      "pubmed": "24581940",
      "registration": "ISRCTN47772397",
      "publication_date": "2014-02-26 00:00:00",
      "arms": 2,
      "disease": "prostate_cancer",
      "subjects": 836,
      "weibull_by_arm": {
        "control": {
          "scale": 226.56726009167815,
          "shape": 1.7095260395787304
        },
        "escalated_dose": {
          "scale": 232.00398944588446,
          "shape": 1.6286831757885811
        }
      },
      "weibull_max_diff": 0.9870142268795672,
      "time_scale": "Months",
      "title": null,
      "condition_list": null,
      "data_index": null,
      "hazard_ratios": {
        "control": {
          "escalated_dose": 1.0306721858816579
        },
        "escalated_dose": {
          "control": 0.9702405999678546
        }
      },
      "min_hazard_ratio": 0.9702405999678546
    },
    {
      "identifier": "NCICBR26",
      "pubmed": "25439692",
      "registration": "NCT01000025",
      "publication_date": "2014-10-15 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 720,
      "weibull_by_arm": {
        "dacomitinib": {
          "scale": 10.499090275578485,
          "shape": 1.1550946327061289
        },
        "placebo": {
          "scale": 10.007460605562917,
          "shape": 1.1576258467199954
        }
      },
      "weibull_max_diff": 0.9538356083519857,
      "time_scale": "Months",
      "title": "PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer",
      "condition_list": [
        "Lung Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "dacomitinib": {
          "placebo": 1.0549722936157826
        },
        "placebo": {
          "dacomitinib": 0.9478921920997829
        }
      },
      "min_hazard_ratio": 0.9478921920997829
    },
    {
      "identifier": "NeoALTTO",
      "pubmed": "25130998",
      "registration": "NCT00553358",
      "publication_date": "2014-08-15 00:00:00",
      "arms": 3,
      "disease": "breast_cancer",
      "subjects": 455,
      "weibull_by_arm": {
        "lapatinib": {
          "scale": 8.757411587299698,
          "shape": 1.3541536830719016
        },
        "lapatinib_trastuzumab": {
          "scale": 9.258128498888464,
          "shape": 1.6024242078143285
        },
        "trastuzumab": {
          "scale": 8.043400240029655,
          "shape": 1.5220574496701038
        }
      },
      "weibull_max_diff": 0.8583640566096085,
      "time_scale": "Unknown",
      "title": "Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study",
      "condition_list": [
        "Neoplasms, Breast"
      ],
      "data_index": null,
      "hazard_ratios": {
        "lapatinib": {
          "lapatinib_trastuzumab": 0.7310583137470753,
          "trastuzumab": 0.9763934499444237
        },
        "lapatinib_trastuzumab": {
          "lapatinib": 1.367879936792526,
          "trastuzumab": 1.335682748006585
        },
        "trastuzumab": {
          "lapatinib": 1.0241772925216983,
          "lapatinib_trastuzumab": 0.748680778794539
        }
      },
      "min_hazard_ratio": 0.7310583137470753
    },
    {
      "identifier": "NITRO",
      "pubmed": "26347110",
      "registration": "ACTRN12608000588392",
      "publication_date": "2015-09-07 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 372,
      "weibull_by_arm": {
        "chemo": {
          "scale": 15.52350347603232,
          "shape": 1.2217778175589316
        },
        "nitro_chemo": {
          "scale": 14.87292011744397,
          "shape": 1.1369049795165544
        }
      },
      "weibull_max_diff": 0.9368729264187624,
      "time_scale": "Months",
      "title": null,
      "condition_list": null,
      "data_index": {
        "age": [
          {
            "value_range": {
              "relation": "<",
              "lower": null,
              "upper": 50.0
            },
            "groups": [
              {
                "group_name": "Chemotherapy + nitroglycerin",
                "count": 11,
                "percentage": 6.0
              },
              {
                "group_name": "Chemotherapy alone",
                "count": 8,
                "percentage": 4.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 50.0,
              "upper": 59.0
            },
            "groups": [
              {
                "group_name": "Chemotherapy + nitroglycerin",
                "count": 49,
                "percentage": 26.0
              },
              {
                "group_name": "Chemotherapy alone",
                "count": 43,
                "percentage": 23.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 60.0,
              "upper": 69.0
            },
            "groups": [
              {
                "group_name": "Chemotherapy + nitroglycerin",
                "count": 77,
                "percentage": 41.0
              },
              {
                "group_name": "Chemotherapy alone",
                "count": 80,
                "percentage": 43.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 70.0,
              "upper": 79.0
            },
            "groups": [
              {
                "group_name": "Chemotherapy + nitroglycerin",
                "count": 48,
                "percentage": 26.0
              },
              {
                "group_name": "Chemotherapy alone",
                "count": 51,
                "percentage": 28.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "≥",
              "lower": 80.0,
              "upper": null
            },
            "groups": [
              {
                "group_name": "Chemotherapy + nitroglycerin",
                "count": 2,
                "percentage": 1.0
              },
              {
                "group_name": "Chemotherapy alone",
                "count": 3,
                "percentage": 2.0
              }
            ]
          }
        ],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "Chemotherapy + nitroglycerin",
                "count": 60,
                "percentage": 32.0
              },
              {
                "group_name": "Chemotherapy alone",
                "count": 65,
                "percentage": 35.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "Chemotherapy + nitroglycerin",
                "count": 114,
                "percentage": 61.0
              },
              {
                "group_name": "Chemotherapy alone",
                "count": 106,
                "percentage": 57.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 2.0,
              "upper": 2.0
            },
            "groups": [
              {
                "group_name": "Chemotherapy + nitroglycerin",
                "count": 13,
                "percentage": 7.0
              },
              {
                "group_name": "Chemotherapy alone",
                "count": 14,
                "percentage": 8.0
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "chemo": {
          "nitro_chemo": 1.0471217930089916
        },
        "nitro_chemo": {
          "chemo": 0.9549987467326191
        }
      },
      "min_hazard_ratio": 0.9549987467326191
    },
    {
      "identifier": "NO16968",
      "pubmed": "26324362",
      "registration": "NCT00069121",
      "publication_date": "2015-08-31 00:00:00",
      "arms": 2,
      "disease": "colorectal_cancer",
      "subjects": 1886,
      "weibull_by_arm": {
        "fu_fa": {
          "scale": 142.50328112487975,
          "shape": 0.7925950128509885
        },
        "xelox": {
          "scale": 197.24379502313843,
          "shape": 0.766530260942291
        }
      },
      "weibull_max_diff": 0.7339227467734017,
      "time_scale": "Months",
      "title": "A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer",
      "condition_list": [
        "Colorectal Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "fu_fa": {
          "xelox": 0.8028927481286159
        },
        "xelox": {
          "fu_fa": 1.2454963658979414
        }
      },
      "min_hazard_ratio": 0.8028927481286159
    },
    {
      "identifier": "NOAH",
      "pubmed": "24657003",
      "registration": "ISRCTN86043495",
      "publication_date": "2014-03-20 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 235,
      "weibull_by_arm": {
        "chemotherapy": {
          "scale": 80.97529438914245,
          "shape": 0.9678508913555205
        },
        "chemotherapy_trastuzumab": {
          "scale": 118.65340940156564,
          "shape": 1.1126300767835744
        }
      },
      "weibull_max_diff": 0.6496388416911041,
      "time_scale": "Months",
      "title": null,
      "condition_list": null,
      "data_index": null,
      "hazard_ratios": {
        "chemotherapy": {
          "chemotherapy_trastuzumab": 0.6276780855082638
        },
        "chemotherapy_trastuzumab": {
          "chemotherapy": 1.5931733528505263
        }
      },
      "min_hazard_ratio": 0.6276780855082638
    },
    {
      "identifier": "NSABPB35",
      "pubmed": "26686957",
      "registration": "NCT00053898",
      "publication_date": "2015-12-10 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 3077,
      "weibull_by_arm": {
        "anastrozole": {
          "scale": 506.6773903855825,
          "shape": 1.146734057102217
        },
        "tamoxifen": {
          "scale": 379.13589285552985,
          "shape": 1.2987923023408883
        }
      },
      "weibull_max_diff": 0.776809299388879,
      "time_scale": "Unknown",
      "title": "Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy",
      "condition_list": [
        "Breast Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "anastrozole": {
          "tamoxifen": 1.145570861601498
        },
        "tamoxifen": {
          "anastrozole": 0.8729272308847039
        }
      },
      "min_hazard_ratio": 0.8729272308847039
    },
    {
      "identifier": "NSABPB40",
      "pubmed": "26272770",
      "registration": "NCT00408408",
      "publication_date": "2015-08-11 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 1186,
      "weibull_by_arm": {
        "bev": {
          "scale": 258.5172113716244,
          "shape": 1.2924213271291236
        },
        "no_bev": {
          "scale": 157.81303175591523,
          "shape": 1.4747177574247503
        }
      },
      "weibull_max_diff": 0.6322338580561608,
      "time_scale": "Months",
      "title": "Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery",
      "condition_list": [
        "Breast Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "bev": {
          "no_bev": 1.5368084958298838
        },
        "no_bev": {
          "bev": 0.6506991617455858
        }
      },
      "min_hazard_ratio": 0.6506991617455858
    },
    {
      "identifier": "NSABPR04",
      "pubmed": "26374429",
      "registration": "NCT00058474",
      "publication_date": "2015-09-14 00:00:00",
      "arms": 2,
      "disease": "colorectal_cancer",
      "subjects": 1284,
      "weibull_by_arm": {
        "no_oxali": {
          "scale": 2142.7008689534246,
          "shape": 0.5195560453683031
        },
        "oxali": {
          "scale": 3112.7144281955443,
          "shape": 0.4884904978273978
        }
      },
      "weibull_max_diff": 0.7199554730749205,
      "time_scale": "Months",
      "title": "Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer",
      "condition_list": [
        "Colorectal Cancer"
      ],
      "data_index": {
        "age": [
          {
            "value_range": {
              "relation": "<",
              "lower": null,
              "upper": 59.0
            },
            "groups": [
              {
                "group_name": "5-FU (2 Arm) Grp 1",
                "count": 86,
                "percentage": 59.2
              },
              {
                "group_name": "CAPE (2 Arm) Grp 2",
                "count": 74,
                "percentage": 52.7
              },
              {
                "group_name": "5-FU (4 Arm) Grp 3",
                "count": 184,
                "percentage": 56.1
              },
              {
                "group_name": "5-FU + OX (4 Arm) Grp 4",
                "count": 201,
                "percentage": 61.4
              },
              {
                "group_name": "CAPE (4 Arm) Grp 5",
                "count": 186,
                "percentage": 57.1
              },
              {
                "group_name": "CAPE + OX (4 Arm) Grp 6",
                "count": 201,
                "percentage": 61.2
              }
            ]
          },
          {
            "value_range": {
              "relation": "≥",
              "lower": 60.0,
              "upper": null
            },
            "groups": [
              {
                "group_name": "5-FU (2 Arm) Grp 1",
                "count": 60,
                "percentage": 40.8
              },
              {
                "group_name": "CAPE (2 Arm) Grp 2",
                "count": 67,
                "percentage": 47.3
              },
              {
                "group_name": "5-FU (4 Arm) Grp 3",
                "count": 144,
                "percentage": 43.9
              },
              {
                "group_name": "5-FU + OX (4 Arm) Grp 4",
                "count": 126,
                "percentage": 38.6
              },
              {
                "group_name": "CAPE (4 Arm) Grp 5",
                "count": 139,
                "percentage": 42.9
              },
              {
                "group_name": "CAPE + OX (4 Arm) Grp 6",
                "count": 127,
                "percentage": 38.8
              }
            ]
          }
        ],
        "ecog": []
      },
      "hazard_ratios": {
        "no_oxali": {
          "oxali": 0.944210432428928
        },
        "oxali": {
          "no_oxali": 1.0590859470039495
        }
      },
      "min_hazard_ratio": 0.944210432428928
    },
    {
      "identifier": "NTR1527",
      "pubmed": "25230595",
      "registration": "NTR1527",
      "publication_date": "2014-09-14 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 495,
      "weibull_by_arm": {
        "control": {
          "scale": 4.430071351077059,
          "shape": 1.2757153238411632
        },
        "thoracic_radiotherapy": {
          "scale": 5.974445303151761,
          "shape": 1.2064329312628073
        }
      },
      "weibull_max_diff": 0.753838851532133,
      "time_scale": "Unknown",
      "title": null,
      "condition_list": null,
      "data_index": null,
      "hazard_ratios": {
        "control": {
          "thoracic_radiotherapy": 0.728625519910647
        },
        "thoracic_radiotherapy": {
          "control": 1.3724471249958858
        }
      },
      "min_hazard_ratio": 0.728625519910647
    },
    {
      "identifier": "OMEGA",
      "pubmed": "24504445",
      "registration": "ISRCTN 11114726",
      "publication_date": "2014-02-06 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 78,
      "weibull_by_arm": {
        "capecitabine": {
          "scale": 9.125337382961993,
          "shape": 1.213436588772962
        },
        "peg_doxorubicin": {
          "scale": 7.110911845750127,
          "shape": 1.7783788327810686
        }
      },
      "weibull_max_diff": 0.8577240570635423,
      "time_scale": "Months",
      "title": null,
      "condition_list": null,
      "data_index": {
        "age": [
          {
            "value_range": {
              "relation": "<",
              "lower": null,
              "upper": 75.0
            },
            "groups": [
              {
                "group_name": "PLD",
                "count": 21,
                "percentage": 52.0
              },
              {
                "group_name": "Capecitabine",
                "count": 15,
                "percentage": 39.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 75.0,
              "upper": 80.0
            },
            "groups": [
              {
                "group_name": "PLD",
                "count": 12,
                "percentage": 30.0
              },
              {
                "group_name": "Capecitabine",
                "count": 20,
                "percentage": 53.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "≥",
              "lower": 80.0,
              "upper": null
            },
            "groups": [
              {
                "group_name": "PLD",
                "count": 7,
                "percentage": 18.0
              },
              {
                "group_name": "Capecitabine",
                "count": 3,
                "percentage": 8.0
              }
            ]
          }
        ],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "PLD",
                "count": 12,
                "percentage": 30.0
              },
              {
                "group_name": "Capecitabine",
                "count": 11,
                "percentage": 29.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "PLD",
                "count": 19,
                "percentage": 48.0
              },
              {
                "group_name": "Capecitabine",
                "count": 18,
                "percentage": 47.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 2.0,
              "upper": 2.0
            },
            "groups": [
              {
                "group_name": "PLD",
                "count": 8,
                "percentage": 20.0
              },
              {
                "group_name": "Capecitabine",
                "count": 9,
                "percentage": 24.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 3.0,
              "upper": 3.0
            },
            "groups": [
              {
                "group_name": "PLD",
                "count": 1,
                "percentage": 2.0
              },
              {
                "group_name": "Capecitabine",
                "count": 0,
                "percentage": 0.0
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "capecitabine": {
          "peg_doxorubicin": 1.5201413532851178
        },
        "peg_doxorubicin": {
          "capecitabine": 0.6578335612270132
        }
      },
      "min_hazard_ratio": 0.6578335612270132
    },
    {
      "identifier": "OPTIMAL",
      "pubmed": "26141208",
      "registration": "NCT00874419",
      "publication_date": "2015-07-03 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 154,
      "weibull_by_arm": {
        "erlotinib": {
          "scale": 31.146763609042182,
          "shape": 1.8553990239620501
        },
        "gem_carboplatin": {
          "scale": 35.52979213574665,
          "shape": 1.4356845134224414
        }
      },
      "weibull_max_diff": 0.9287535237174801,
      "time_scale": "Months",
      "title": "Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation",
      "condition_list": [
        "Non-small Cell Lung Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "erlotinib": {
          "gem_carboplatin": 0.8043030816547999
        },
        "gem_carboplatin": {
          "erlotinib": 1.2433124064905565
        }
      },
      "min_hazard_ratio": 0.8043030816547999
    },
    {
      "identifier": "OPTIMOX3",
      "pubmed": "26474518",
      "registration": "NCT00265824",
      "publication_date": "2015-10-14 00:00:00",
      "arms": 2,
      "disease": "colorectal_cancer",
      "subjects": 452,
      "weibull_by_arm": {
        "bev": {
          "scale": 29.38153317777502,
          "shape": 1.561073687301702
        },
        "bev_erlotinib": {
          "scale": 34.311669742469974,
          "shape": 1.3659179107522426
        }
      },
      "weibull_max_diff": 0.8855250242567492,
      "time_scale": "Months",
      "title": "Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM)",
      "condition_list": [
        "Colorectal Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "bev": {
          "bev_erlotinib": 0.805101672454462
        },
        "bev_erlotinib": {
          "bev": 1.2420791487755378
        }
      },
      "min_hazard_ratio": 0.805101672454462
    },
    {
      "identifier": "PALOMA2",
      "pubmed": "27959613",
      "registration": "NCT01740427",
      "publication_date": "2016-11-17 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 666,
      "weibull_by_arm": {
        "palbociclib_letrozole": {
          "scale": 41.742055850999506,
          "shape": 1.0993585480332844
        },
        "placebo_letrozole": {
          "scale": 28.420144049811864,
          "shape": 1.1026693373805827
        }
      },
      "weibull_max_diff": 0.6815334418808289,
      "time_scale": "Unknown",
      "title": "A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)",
      "condition_list": [
        "Breast Neoplasms"
      ],
      "data_index": {
        "age": [
          {
            "value_range": {
              "relation": "<",
              "lower": null,
              "upper": 65.0
            },
            "groups": [
              {
                "group_name": "Palbociclib-Letrozole",
                "count": 263,
                "percentage": 59.2
              },
              {
                "group_name": "Placebo-Letrozole",
                "count": 141,
                "percentage": 63.5
              }
            ]
          },
          {
            "value_range": {
              "relation": "≥",
              "lower": 65.0,
              "upper": null
            },
            "groups": [
              {
                "group_name": "Palbociclib-Letrozole",
                "count": 181,
                "percentage": 40.8
              },
              {
                "group_name": "Placebo-Letrozole",
                "count": 81,
                "percentage": 36.5
              }
            ]
          }
        ],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "Palbociclib-Letrozole",
                "count": 257,
                "percentage": 57.9
              },
              {
                "group_name": "Placebo-Letrozole",
                "count": 102,
                "percentage": 45.9
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "Palbociclib-Letrozole",
                "count": 178,
                "percentage": 40.1
              },
              {
                "group_name": "Placebo-Letrozole",
                "count": 117,
                "percentage": 52.7
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 2.0,
              "upper": 2.0
            },
            "groups": [
              {
                "group_name": "Palbociclib-Letrozole",
                "count": 9,
                "percentage": 2.0
              },
              {
                "group_name": "Placebo-Letrozole",
                "count": 3,
                "percentage": 1.4
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "palbociclib_letrozole": {
          "placebo_letrozole": 1.5104607091590372
        },
        "placebo_letrozole": {
          "palbociclib_letrozole": 0.6620496607003827
        }
      },
      "min_hazard_ratio": 0.6620496607003827
    },
    {
      "identifier": "PALOMA3",
      "pubmed": "26947331",
      "registration": "NCT01942135",
      "publication_date": "2016-03-02 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 521,
      "weibull_by_arm": {
        "palbociclib_fulvestrant": {
          "scale": 10.514811211751766,
          "shape": 1.4313831584952303
        },
        "placebo_fulvestrant": {
          "scale": 5.674821087356917,
          "shape": 1.4793739737396174
        }
      },
      "weibull_max_diff": 0.5441994817061294,
      "time_scale": "Unknown",
      "title": "Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)",
      "condition_list": [
        "Metastatic Breast Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "palbociclib_fulvestrant": {
          "placebo_fulvestrant": 2.3672223191837185
        },
        "placebo_fulvestrant": {
          "palbociclib_fulvestrant": 0.4224360305730926
        }
      },
      "min_hazard_ratio": 0.4224360305730926
    },
    {
      "identifier": "PEGASE07",
      "pubmed": "25943350",
      "registration": "NCT02324088",
      "publication_date": "2015-05-05 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 174,
      "weibull_by_arm": {
        "arma": {
          "scale": 91.0074400104293,
          "shape": 1.0592501065315914
        },
        "armb": {
          "scale": 93.66280256643522,
          "shape": 0.8973277038818576
        }
      },
      "weibull_max_diff": 0.9668829860982271,
      "time_scale": "Months",
      "title": "Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer",
      "condition_list": [
        "Inflammatory Breast Cancer"
      ],
      "data_index": {
        "age": [],
        "ecog": []
      },
      "hazard_ratios": {
        "arma": {
          "armb": 1.0933760676898459
        },
        "armb": {
          "arma": 0.9145983980725527
        }
      },
      "min_hazard_ratio": 0.9145983980725527
    },
    {
      "identifier": "PETACC8",
      "pubmed": "24928083",
      "registration": "EudraCT 2005-003463-23",
      "publication_date": "2014-06-11 00:00:00",
      "arms": 2,
      "disease": "colorectal_cancer",
      "subjects": 1602,
      "weibull_by_arm": {
        "folfox4": null,
        "folfox4_cetuximab": {
          "scale": 165.40395359529717,
          "shape": 1.4230442971181856
        }
      },
      "weibull_max_diff": null,
      "time_scale": "Months",
      "title": null,
      "condition_list": null,
      "data_index": null,
      "hazard_ratios": {
        "folfox4": {
          "folfox4_cetuximab": 1.1796639885868696
        },
        "folfox4_cetuximab": {
          "folfox4": 0.8476990140200086
        }
      },
      "min_hazard_ratio": 0.8476990140200086
    },
    {
      "identifier": "PREVAIL",
      "pubmed": "24881730",
      "registration": "NCT01212991",
      "publication_date": "2014-06-01 00:00:00",
      "arms": 2,
      "disease": "prostate_cancer",
      "subjects": 1717,
      "weibull_by_arm": {
        "enzalutamide": {
          "scale": 40.405783930556936,
          "shape": 1.9631710809449592
        },
        "placebo": {
          "scale": 38.04338004518768,
          "shape": 1.5831271867929544
        }
      },
      "weibull_max_diff": 0.9002673502675894,
      "time_scale": "Months",
      "title": "A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer",
      "condition_list": [
        "Prostate Cancer"
      ],
      "data_index": {
        "age": [
          {
            "value_range": {
              "relation": "<",
              "lower": null,
              "upper": 65.0
            },
            "groups": [
              {
                "group_name": "Enzalutamide",
                "count": 179,
                "percentage": 20.5
              },
              {
                "group_name": "Placebo",
                "count": 179,
                "percentage": 21.2
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 65.0,
              "upper": 74.0
            },
            "groups": [
              {
                "group_name": "Enzalutamide",
                "count": 376,
                "percentage": 43.1
              },
              {
                "group_name": "Placebo",
                "count": 374,
                "percentage": 44.3
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 75.0,
              "upper": 84.0
            },
            "groups": [
              {
                "group_name": "Enzalutamide",
                "count": 274,
                "percentage": 31.4
              },
              {
                "group_name": "Placebo",
                "count": 240,
                "percentage": 28.4
              }
            ]
          },
          {
            "value_range": {
              "relation": "≥",
              "lower": 85.0,
              "upper": null
            },
            "groups": [
              {
                "group_name": "Enzalutamide",
                "count": 43,
                "percentage": 4.9
              },
              {
                "group_name": "Placebo",
                "count": 52,
                "percentage": 6.2
              }
            ]
          }
        ],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "Enzalutamide",
                "count": 584,
                "percentage": 67.0
              },
              {
                "group_name": "Placebo",
                "count": 585,
                "percentage": 69.2
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "Enzalutamide",
                "count": 288,
                "percentage": 33.0
              },
              {
                "group_name": "Placebo",
                "count": 260,
                "percentage": 30.8
              }
            ]
          },
          {
            "value_range": {
              "relation": "≥",
              "lower": 2.0,
              "upper": null
            },
            "groups": [
              {
                "group_name": "Enzalutamide",
                "count": 0,
                "percentage": null
              },
              {
                "group_name": "Placebo",
                "count": 0,
                "percentage": null
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "enzalutamide": {
          "placebo": 1.3792372683996428
        },
        "placebo": {
          "enzalutamide": 0.7250384128325653
        }
      },
      "min_hazard_ratio": 0.7250384128325653
    },
    {
      "identifier": "PROCLAIM",
      "pubmed": "26811519",
      "registration": null,
      "publication_date": "2016-01-25 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 598,
      "weibull_by_arm": {
        "eto_cis": {
          "scale": 17.870718982302556,
          "shape": 1.0767587864953252
        },
        "pem_cis": {
          "scale": 20.708438324994034,
          "shape": 1.0505120886701775
        }
      },
      "weibull_max_diff": 0.8703383041031278,
      "time_scale": "Months",
      "title": null,
      "condition_list": null,
      "data_index": {
        "age": [],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "Arm A",
                "count": 148,
                "percentage": 49.2
              },
              {
                "group_name": "Arm B",
                "count": 145,
                "percentage": 48.8
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "Arm A",
                "count": 152,
                "percentage": 50.5
              },
              {
                "group_name": "Arm B",
                "count": 149,
                "percentage": 50.2
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "eto_cis": {
          "pem_cis": 0.8592707804837656
        },
        "pem_cis": {
          "eto_cis": 1.1637774991452687
        }
      },
      "min_hazard_ratio": 0.8592707804837656
    },
    {
      "identifier": "PROCTOR-SCRIPT",
      "pubmed": "25480874",
      "registration": "ISRCTN36266738",
      "publication_date": "2014-12-05 00:00:00",
      "arms": 2,
      "disease": "colorectal_cancer",
      "subjects": 437,
      "weibull_by_arm": {
        "chemotherapy": {
          "scale": 169.89463186608157,
          "shape": 1.427704816125063
        },
        "observation": {
          "scale": 176.71064230856962,
          "shape": 1.2856387153652373
        }
      },
      "weibull_max_diff": 0.9890923376152434,
      "time_scale": "Months",
      "title": null,
      "condition_list": null,
      "data_index": {
        "age": [],
        "ecog": []
      },
      "hazard_ratios": {
        "chemotherapy": {
          "observation": 1.0809541394655215
        },
        "observation": {
          "chemotherapy": 0.9251086271749239
        }
      },
      "min_hazard_ratio": 0.9251086271749239
    },
    {
      "identifier": "PROFILE1014",
      "pubmed": "27022118",
      "registration": "NCT01154140",
      "publication_date": "2016-03-28 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 343,
      "weibull_by_arm": {
        "chemotherapy": {
          "scale": 56.31937809597151,
          "shape": 0.947438593798252
        },
        "crizotinib": {
          "scale": 52.89249449793867,
          "shape": 1.1035032967157778
        }
      },
      "weibull_max_diff": 0.9919655507384048,
      "time_scale": "Unknown",
      "title": "A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung",
      "condition_list": [
        "Non Squamous Lung Cancer"
      ],
      "data_index": {
        "age": [],
        "ecog": [
          {
            "value_range": {
              "relation": "-",
              "lower": 0.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "Crizotinib (Brain Metastases Present)",
                "count": 35,
                "percentage": 90.0
              },
              {
                "group_name": "Chemotherapy (Brain Metastases Present)",
                "count": 34,
                "percentage": 85.0
              },
              {
                "group_name": "Crizotinib (Brain Metastases Absent)",
                "count": 125,
                "percentage": 95.0
              },
              {
                "group_name": "Chemotherapy (Brain Metastases Absent)",
                "count": 129,
                "percentage": 98.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 2.0,
              "upper": 2.0
            },
            "groups": [
              {
                "group_name": "Crizotinib (Brain Metastases Present)",
                "count": 4,
                "percentage": 10.0
              },
              {
                "group_name": "Chemotherapy (Brain Metastases Present)",
                "count": 6,
                "percentage": 15.0
              },
              {
                "group_name": "Crizotinib (Brain Metastases Absent)",
                "count": 6,
                "percentage": 5.0
              },
              {
                "group_name": "Chemotherapy (Brain Metastases Absent)",
                "count": 2,
                "percentage": 2.0
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "chemotherapy": {
          "crizotinib": 0.8858915119991972
        },
        "crizotinib": {
          "chemotherapy": 1.1288063904611676
        }
      },
      "min_hazard_ratio": 0.8858915119991972
    },
    {
      "identifier": "PROSE",
      "pubmed": "24831979",
      "registration": "NCT00989690",
      "publication_date": "2014-05-13 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 263,
      "weibull_by_arm": {
        "chemotherapy": {
          "scale": 13.831697470196676,
          "shape": 1.0981264114813398
        },
        "erlotinib": {
          "scale": 12.07644677291705,
          "shape": 0.998082117738984
        }
      },
      "weibull_max_diff": 0.8443729315563747,
      "time_scale": "Months",
      "title": "Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer",
      "condition_list": [
        "Lung Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "chemotherapy": {
          "erlotinib": 1.1469139083851045
        },
        "erlotinib": {
          "chemotherapy": 0.8719050250319446
        }
      },
      "min_hazard_ratio": 0.8719050250319446
    },
    {
      "identifier": "QUARTZ",
      "pubmed": "27604504",
      "registration": "ISRCTN3826061",
      "publication_date": "2016-09-04 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 538,
      "weibull_by_arm": {
        "osc": {
          "scale": 12.611075931296044,
          "shape": 1.1130678309302389
        },
        "osc_wbrt": {
          "scale": 13.877453855007047,
          "shape": 1.139763258267914
        }
      },
      "weibull_max_diff": 0.9017639995989009,
      "time_scale": "Unknown",
      "title": null,
      "condition_list": null,
      "data_index": null,
      "hazard_ratios": {
        "osc": {
          "osc_wbrt": 0.9180794469586869
        },
        "osc_wbrt": {
          "osc": 1.0892303528988592
        }
      },
      "min_hazard_ratio": 0.9180794469586869
    },
    {
      "identifier": "QUASAR2",
      "pubmed": "27660192",
      "registration": "ISRCTN45133151",
      "publication_date": "2016-09-19 00:00:00",
      "arms": 2,
      "disease": "colorectal_cancer",
      "subjects": 1939,
      "weibull_by_arm": {
        "cap": {
          "scale": 246.16334377241841,
          "shape": 1.124160117060423
        },
        "cap_bev": {
          "scale": 218.38610804121342,
          "shape": 1.1178250460224664
        }
      },
      "weibull_max_diff": 0.8855216152997422,
      "time_scale": "Months",
      "title": null,
      "condition_list": null,
      "data_index": null,
      "hazard_ratios": {
        "cap": {
          "cap_bev": 1.1561864687439267
        },
        "cap_bev": {
          "cap": 0.8649123882987433
        }
      },
      "min_hazard_ratio": 0.8649123882987433
    },
    {
      "identifier": "R98",
      "pubmed": "25739671",
      "registration": "NR",
      "publication_date": "2015-03-03 00:00:00",
      "arms": 2,
      "disease": "colorectal_cancer",
      "subjects": 357,
      "weibull_by_arm": {
        "5fulv": {
          "scale": 179.32580568234897,
          "shape": 1.192729316379432
        },
        "5fulv_cpt11": {
          "scale": 201.80456896484066,
          "shape": 1.1885214024886976
        }
      },
      "weibull_max_diff": 0.8895785140735387,
      "time_scale": "Months",
      "title": null,
      "condition_list": null,
      "data_index": {
        "age": [],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "Control arm",
                "count": null,
                "percentage": 58.0
              },
              {
                "group_name": "LV5-FU2 + irinotecan arm",
                "count": null,
                "percentage": 65.0
              },
              {
                "group_name": "All",
                "count": null,
                "percentage": 62.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "Control arm",
                "count": null,
                "percentage": 28.0
              },
              {
                "group_name": "LV5-FU2 + irinotecan arm",
                "count": null,
                "percentage": 23.0
              },
              {
                "group_name": "All",
                "count": null,
                "percentage": 26.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 2.0,
              "upper": 2.0
            },
            "groups": [
              {
                "group_name": "Control arm",
                "count": null,
                "percentage": 2.0
              },
              {
                "group_name": "LV5-FU2 + irinotecan arm",
                "count": null,
                "percentage": 2.0
              },
              {
                "group_name": "All",
                "count": null,
                "percentage": 2.0
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "5fulv": {
          "5fulv_cpt11": 0.8654476156348614
        },
        "5fulv_cpt11": {
          "5fulv": 1.1554714369008179
        }
      },
      "min_hazard_ratio": 0.8654476156348614
    },
    {
      "identifier": "RADIANT",
      "pubmed": "26324372",
      "registration": "NCT00373425",
      "publication_date": "2015-08-31 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 973,
      "weibull_by_arm": {
        "erlotinib": {
          "scale": 69.33974498748108,
          "shape": 0.9680459665192714
        },
        "placebo": {
          "scale": 68.66773131196642,
          "shape": 0.834790007027952
        }
      },
      "weibull_max_diff": 0.9322298714025169,
      "time_scale": "Unknown",
      "title": "A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors",
      "condition_list": [
        "Non-small Cell Lung Cancer"
      ],
      "data_index": {
        "age": [],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "Erlotinib (ITT)",
                "count": 385,
                "percentage": 61.8
              },
              {
                "group_name": "Placebo (ITT)",
                "count": 211,
                "percentage": 60.3
              },
              {
                "group_name": "Total (ITT)",
                "count": 596,
                "percentage": 61.3
              },
              {
                "group_name": "Erlotinib (EGFRm+)",
                "count": 61,
                "percentage": 59.8
              },
              {
                "group_name": "Placebo (EGFRm+)",
                "count": 38,
                "percentage": 64.4
              },
              {
                "group_name": "Total (EGFRm+)",
                "count": 99,
                "percentage": 61.5
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "Erlotinib (ITT)",
                "count": 230,
                "percentage": 36.9
              },
              {
                "group_name": "Placebo (ITT)",
                "count": 134,
                "percentage": 38.3
              },
              {
                "group_name": "Total (ITT)",
                "count": 364,
                "percentage": 37.4
              },
              {
                "group_name": "Erlotinib (EGFRm+)",
                "count": 40,
                "percentage": 39.2
              },
              {
                "group_name": "Placebo (EGFRm+)",
                "count": 21,
                "percentage": 35.6
              },
              {
                "group_name": "Total (EGFRm+)",
                "count": 61,
                "percentage": 37.9
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 2.0,
              "upper": 2.0
            },
            "groups": [
              {
                "group_name": "Erlotinib (ITT)",
                "count": 6,
                "percentage": 1.0
              },
              {
                "group_name": "Placebo (ITT)",
                "count": 5,
                "percentage": 1.4
              },
              {
                "group_name": "Total (ITT)",
                "count": 11,
                "percentage": 1.1
              },
              {
                "group_name": "Erlotinib (EGFRm+)",
                "count": 1,
                "percentage": 1.0
              },
              {
                "group_name": "Placebo (EGFRm+)",
                "count": 0,
                "percentage": 0.0
              },
              {
                "group_name": "Total (EGFRm+)",
                "count": 1,
                "percentage": 0.6
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "erlotinib": {
          "placebo": 1.113944065403075
        },
        "placebo": {
          "erlotinib": 0.8977111428284823
        }
      },
      "min_hazard_ratio": 0.8977111428284823
    },
    {
      "identifier": "RAISE",
      "pubmed": "25877855",
      "registration": "NCT01183780",
      "publication_date": "2015-04-13 00:00:00",
      "arms": 2,
      "disease": "colorectal_cancer",
      "subjects": 1072,
      "weibull_by_arm": {
        "placebo_folfiri": {
          "scale": 6.8114778047198135,
          "shape": 1.2776826143316853
        },
        "ramucirumab_folfiri": {
          "scale": 8.246810477406692,
          "shape": 1.3368423231468676
        }
      },
      "weibull_max_diff": 0.8155342866430518,
      "time_scale": "Months",
      "title": "A Study in Second Line Metastatic Colorectal Cancer",
      "condition_list": [
        "Colorectal Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "placebo_folfiri": {
          "ramucirumab_folfiri": 0.8016383883334508
        },
        "ramucirumab_folfiri": {
          "placebo_folfiri": 1.2474452503190732
        }
      },
      "min_hazard_ratio": 0.8016383883334508
    },
    {
      "identifier": "RECOURSE",
      "pubmed": "25970050",
      "registration": "NCT01607957",
      "publication_date": "2015-05-14 00:00:00",
      "arms": 2,
      "disease": "colorectal_cancer",
      "subjects": 800,
      "weibull_by_arm": {
        "placebo": {
          "scale": 7.501213073395242,
          "shape": 1.3950058827100156
        },
        "tas102": {
          "scale": 9.758244271178215,
          "shape": 1.530655280380222
        }
      },
      "weibull_max_diff": 0.7510135864664694,
      "time_scale": "Months",
      "title": "Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies",
      "condition_list": [
        "Colorectal Cancer"
      ],
      "data_index": {
        "age": [],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "TAS-102",
                "count": 301,
                "percentage": 56.0
              },
              {
                "group_name": "Placebo",
                "count": 147,
                "percentage": 55.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "TAS-102",
                "count": 233,
                "percentage": 44.0
              },
              {
                "group_name": "Placebo",
                "count": 119,
                "percentage": 45.0
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "placebo": {
          "tas102": 0.6811884930487105
        },
        "tas102": {
          "placebo": 1.4680224492994949
        }
      },
      "min_hazard_ratio": 0.6811884930487105
    },
    {
      "identifier": "REVEL",
      "pubmed": "24933332",
      "registration": "NCT01168973",
      "publication_date": "2014-06-02 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 1253,
      "weibull_by_arm": {
        "placebo_docetaxel": {
          "scale": 5.221983031658977,
          "shape": 1.1633998461117394
        },
        "ramucirumab_docetaxel": {
          "scale": 6.6635469497272135,
          "shape": 1.279365128837868
        }
      },
      "weibull_max_diff": 0.7616025403465446,
      "time_scale": "Months",
      "title": "A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy",
      "condition_list": [
        "Non-Small Cell Lung Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "placebo_docetaxel": {
          "ramucirumab_docetaxel": 0.768255995434902
        },
        "ramucirumab_docetaxel": {
          "placebo_docetaxel": 1.3016494579178781
        }
      },
      "min_hazard_ratio": 0.768255995434902
    },
    {
      "identifier": "ROSE",
      "pubmed": "25185099",
      "registration": "NCT00703326",
      "publication_date": "2014-09-02 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 1144,
      "weibull_by_arm": {
        "pbo_doc": {
          "scale": 11.53610953234385,
          "shape": 1.2641232860454192
        },
        "ram_doc": {
          "scale": 13.012706288333046,
          "shape": 1.327678333005292
        }
      },
      "weibull_max_diff": 0.8743074645468384,
      "time_scale": "Months",
      "title": "Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer",
      "condition_list": [
        "Breast Cancer"
      ],
      "data_index": {
        "age": [],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "RAM Plus DOC Arm",
                "count": null,
                "percentage": 58.0
              },
              {
                "group_name": "PBO Plus DOC Arm",
                "count": null,
                "percentage": 62.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "RAM Plus DOC Arm",
                "count": null,
                "percentage": 42.0
              },
              {
                "group_name": "PBO Plus DOC Arm",
                "count": null,
                "percentage": 37.0
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "pbo_doc": {
          "ram_doc": 0.8549664512752414
        },
        "ram_doc": {
          "pbo_doc": 1.1696365377944726
        }
      },
      "min_hazard_ratio": 0.8549664512752414
    },
    {
      "identifier": "RTOG0415",
      "pubmed": "27044935",
      "registration": null,
      "publication_date": "2016-04-04 00:00:00",
      "arms": 2,
      "disease": "prostate_cancer",
      "subjects": 1092,
      "weibull_by_arm": {
        "70gy": {
          "scale": 32.998376917763665,
          "shape": 1.02957196025504
        },
        "73.8gy": {
          "scale": 16.846376498696152,
          "shape": 1.507759835561018
        }
      },
      "weibull_max_diff": 0.5715396159096268,
      "time_scale": "Unknown",
      "title": null,
      "condition_list": null,
      "data_index": {
        "age": [
          {
            "value_range": {
              "relation": "≤",
              "lower": null,
              "upper": 59.0
            },
            "groups": [
              {
                "group_name": "3D-CRT/IMRT 73.8 Gy",
                "count": 87,
                "percentage": 16.1
              },
              {
                "group_name": "3D-CRT/IMRT 70 Gy",
                "count": 95,
                "percentage": 17.3
              },
              {
                "group_name": "Total",
                "count": 182,
                "percentage": 16.7
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 60.0,
              "upper": 69.0
            },
            "groups": [
              {
                "group_name": "3D-CRT/IMRT 73.8 Gy",
                "count": 239,
                "percentage": 44.1
              },
              {
                "group_name": "3D-CRT/IMRT 70 Gy",
                "count": 251,
                "percentage": 45.6
              },
              {
                "group_name": "Total",
                "count": 490,
                "percentage": 44.9
              }
            ]
          },
          {
            "value_range": {
              "relation": "≥",
              "lower": 70.0,
              "upper": null
            },
            "groups": [
              {
                "group_name": "3D-CRT/IMRT 73.8 Gy",
                "count": 216,
                "percentage": 39.9
              },
              {
                "group_name": "3D-CRT/IMRT 70 Gy",
                "count": 204,
                "percentage": 37.1
              },
              {
                "group_name": "Total",
                "count": 420,
                "percentage": 38.5
              }
            ]
          }
        ],
        "ecog": []
      },
      "hazard_ratios": {
        "70gy": {
          "73.8gy": 1.1992598049949663
        },
        "73.8gy": {
          "70gy": 0.8338476749032687
        }
      },
      "min_hazard_ratio": 0.8338476749032687
    },
    {
      "identifier": "RTOG0617",
      "pubmed": "25601342",
      "registration": "NCT00533949",
      "publication_date": "2015-01-16 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 465,
      "weibull_by_arm": {
        "cetuximab": {
          "scale": 32.70551340647145,
          "shape": 1.2633729207296849
        },
        "no_cetuximab": {
          "scale": 31.003993918903397,
          "shape": 1.293220905662079
        }
      },
      "weibull_max_diff": 0.9543432467175639,
      "time_scale": "Months",
      "title": "High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery",
      "condition_list": [
        "Lung Cancer",
        "Radiation Toxicity"
      ],
      "data_index": null,
      "hazard_ratios": {
        "cetuximab": {
          "no_cetuximab": 1.0588669460911484
        },
        "no_cetuximab": {
          "cetuximab": 0.944405719426356
        }
      },
      "min_hazard_ratio": 0.944405719426356
    },
    {
      "identifier": "RTOG9804",
      "pubmed": "25605856",
      "registration": "NCT00003857",
      "publication_date": "2015-01-20 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 585,
      "weibull_by_arm": {
        "observation": {
          "scale": 31.547584811117705,
          "shape": 1.28310707587161
        },
        "rt": {
          "scale": 29.166316068223324,
          "shape": 1.459265590140184
        }
      },
      "weibull_max_diff": 0.9569536764688938,
      "time_scale": "Unknown",
      "title": "Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ",
      "condition_list": [
        "Breast Cancer"
      ],
      "data_index": {
        "age": [
          {
            "value_range": {
              "relation": "-",
              "lower": 1.0,
              "upper": 3.0
            },
            "groups": [
              {
                "group_name": "Observation ± Tamoxifen",
                "count": null,
                "percentage": null
              },
              {
                "group_name": "Radiotherapy ± Tamoxifen",
                "count": null,
                "percentage": null
              }
            ]
          },
          {
            "value_range": {
              "relation": "<",
              "lower": null,
              "upper": 50.0
            },
            "groups": [
              {
                "group_name": "Observation ± Tamoxifen",
                "count": 61,
                "percentage": 20.5
              },
              {
                "group_name": "Radiotherapy ± Tamoxifen",
                "count": null,
                "percentage": null
              }
            ]
          },
          {
            "value_range": {
              "relation": "≥",
              "lower": 50.0,
              "upper": null
            },
            "groups": [
              {
                "group_name": "Observation ± Tamoxifen",
                "count": 237,
                "percentage": 79.5
              },
              {
                "group_name": "Radiotherapy ± Tamoxifen",
                "count": null,
                "percentage": null
              }
            ]
          }
        ],
        "ecog": []
      },
      "hazard_ratios": {
        "observation": {
          "rt": 0.8629264967120092
        },
        "rt": {
          "observation": 1.1588472527037694
        }
      },
      "min_hazard_ratio": 0.8629264967120092
    },
    {
      "identifier": "SAKK",
      "pubmed": "26275735",
      "registration": "NCT00030771",
      "publication_date": "2015-08-12 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 232,
      "weibull_by_arm": {
        "chemo_surgery": {
          "scale": 27.992190194819454,
          "shape": 0.6857770980441655
        },
        "crt_surgery": {
          "scale": 31.88237443898964,
          "shape": 0.7567390906373587
        }
      },
      "weibull_max_diff": 0.8350656926361466,
      "time_scale": "Unknown",
      "title": "Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients",
      "condition_list": [
        "Lung Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "chemo_surgery": {
          "crt_surgery": 0.9267188263986699
        },
        "crt_surgery": {
          "chemo_surgery": 1.0790759521807802
        }
      },
      "min_hazard_ratio": 0.9267188263986699
    },
    {
      "identifier": "SAKK4106",
      "pubmed": "25605741",
      "registration": "NCT00544700",
      "publication_date": "2015-01-20 00:00:00",
      "arms": 2,
      "disease": "colorectal_cancer",
      "subjects": 262,
      "weibull_by_arm": {
        "bev": {
          "scale": 33.838583967848486,
          "shape": 1.9665370049086224
        },
        "no_bev": {
          "scale": 30.733962387534717,
          "shape": 2.0000586309101234
        }
      },
      "weibull_max_diff": 0.9110935681776872,
      "time_scale": "Months",
      "title": "Bevacizumab in Treating Patients Who Have Undergone First-Line Therapy for Metastatic Colorectal Cancer",
      "condition_list": [
        "Colorectal Cancer"
      ],
      "data_index": {
        "age": [],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "Bevacizumab continuation",
                "count": 97,
                "percentage": 74.0
              },
              {
                "group_name": "No bevacizumab continuation",
                "count": 91,
                "percentage": 69.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "Bevacizumab continuation",
                "count": 34,
                "percentage": 26.0
              },
              {
                "group_name": "No bevacizumab continuation",
                "count": 40,
                "percentage": 31.0
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "bev": {
          "no_bev": 1.1940065675975848
        },
        "no_bev": {
          "bev": 0.8375163312644603
        }
      },
      "min_hazard_ratio": 0.8375163312644603
    },
    {
      "identifier": "SELECTBC",
      "pubmed": "26617202",
      "registration": "University Hospital Medical Information Network Japan protocol ID C000000416",
      "publication_date": "2015-11-23 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 592,
      "weibull_by_arm": {
        "s-1": {
          "scale": 44.67294055143579,
          "shape": 1.46791296244211
        },
        "taxane": {
          "scale": 46.24435105592767,
          "shape": 1.3789752954627055
        }
      },
      "weibull_max_diff": 0.9817015557467643,
      "time_scale": "Months",
      "title": null,
      "condition_list": null,
      "data_index": null,
      "hazard_ratios": {
        "s-1": {
          "taxane": 0.9581480505444305
        },
        "taxane": {
          "s-1": 1.043680044468899
        }
      },
      "min_hazard_ratio": 0.9581480505444305
    },
    {
      "identifier": "SIRFLOX",
      "pubmed": "26903575",
      "registration": "NCT00724503",
      "publication_date": "2016-02-22 00:00:00",
      "arms": 2,
      "disease": "colorectal_cancer",
      "subjects": 530,
      "weibull_by_arm": {
        "mfolfox6": {
          "scale": 15.674134868642545,
          "shape": 1.3742627082816268
        },
        "mfolfox6_rt": {
          "scale": 16.24762432610999,
          "shape": 1.3018978325620683
        }
      },
      "weibull_max_diff": 0.9791106321189467,
      "time_scale": "Unknown",
      "title": "FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer",
      "condition_list": [
        "Colorectal Cancer",
        "Colorectal Carcinoma",
        "Liver Metastases"
      ],
      "data_index": {
        "age": [],
        "ecog": []
      },
      "hazard_ratios": {
        "mfolfox6": {
          "mfolfox6_rt": 0.913620944745268
        },
        "mfolfox6_rt": {
          "mfolfox6": 1.0945458351754578
        }
      },
      "min_hazard_ratio": 0.913620944745268
    },
    {
      "identifier": "SMART",
      "pubmed": "27345639",
      "registration": "ISRCTN72767336",
      "publication_date": "2016-06-23 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 203,
      "weibull_by_arm": {
        "deferred_rt": {
          "scale": 14.209128490180884,
          "shape": 1.6435647068848205
        },
        "immediate_rt": {
          "scale": 14.578042802746317,
          "shape": 1.6317368016517566
        }
      },
      "weibull_max_diff": 0.976270648446306,
      "time_scale": "Months",
      "title": null,
      "condition_list": null,
      "data_index": null,
      "hazard_ratios": {
        "deferred_rt": {
          "immediate_rt": 0.962042538094348
        },
        "immediate_rt": {
          "deferred_rt": 1.0394550764676578
        }
      },
      "min_hazard_ratio": 0.962042538094348
    },
    {
      "identifier": "SOFT",
      "pubmed": "25495490",
      "registration": "NCT00066690",
      "publication_date": "2014-12-11 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 2033,
      "weibull_by_arm": {
        "tamoxifen": {
          "scale": 31.265270604335818,
          "shape": 0.9849467109859698
        },
        "tamoxifen_os": {
          "scale": 30.15907389829664,
          "shape": 1.1017574914383874
        }
      },
      "weibull_max_diff": 0.9965755529271078,
      "time_scale": "Unknown",
      "title": "Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer",
      "condition_list": [
        "Estrogen Receptor Positive Breast Cancer",
        "Progesterone Receptor Positive Tumor",
        "Recurrent Breast Carcinoma",
        "Stage IA Breast Cancer",
        "Stage IB Breast Cancer",
        "Stage IIA Breast Cancer",
        "Stage IIB Breast Cancer",
        "Stage IIIA Breast Cancer"
      ],
      "data_index": {
        "age": [
          {
            "value_range": {
              "relation": "<",
              "lower": null,
              "upper": 35.0
            },
            "groups": [
              {
                "group_name": "No Chemotherapy",
                "count": 14,
                "percentage": 1.5
              },
              {
                "group_name": "Prior Chemotherapy",
                "count": 219,
                "percentage": 20.2
              },
              {
                "group_name": "Overall",
                "count": 233,
                "percentage": 11.5
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 35.0,
              "upper": 39.0
            },
            "groups": [
              {
                "group_name": "No Chemotherapy",
                "count": 78,
                "percentage": 8.2
              },
              {
                "group_name": "Prior Chemotherapy",
                "count": 309,
                "percentage": 28.5
              },
              {
                "group_name": "Overall",
                "count": 387,
                "percentage": 19.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 40.0,
              "upper": 49.0
            },
            "groups": [
              {
                "group_name": "No Chemotherapy",
                "count": 702,
                "percentage": 74.0
              },
              {
                "group_name": "Prior Chemotherapy",
                "count": 522,
                "percentage": 48.2
              },
              {
                "group_name": "Overall",
                "count": 1224,
                "percentage": 60.2
              }
            ]
          },
          {
            "value_range": {
              "relation": "≥",
              "lower": 50.0,
              "upper": null
            },
            "groups": [
              {
                "group_name": "No Chemotherapy",
                "count": 155,
                "percentage": 16.3
              },
              {
                "group_name": "Prior Chemotherapy",
                "count": 34,
                "percentage": 3.1
              },
              {
                "group_name": "Overall",
                "count": 189,
                "percentage": 9.3
              }
            ]
          }
        ],
        "ecog": []
      },
      "hazard_ratios": {
        "tamoxifen": {
          "tamoxifen_os": 0.8419553281284404
        },
        "tamoxifen_os": {
          "tamoxifen": 1.1877114694705633
        }
      },
      "min_hazard_ratio": 0.8419553281284404
    },
    {
      "identifier": "SQUIRE",
      "pubmed": "26045340",
      "registration": "NCT00981058",
      "publication_date": "2015-06-02 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 1093,
      "weibull_by_arm": {
        "gem_cis": {
          "scale": 14.432263847338989,
          "shape": 1.2500432584526597
        },
        "necitumumab_gem_cis": {
          "scale": 16.331746246386636,
          "shape": 1.2981485889794881
        }
      },
      "weibull_max_diff": 0.8741444225575222,
      "time_scale": "Months",
      "title": "First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin",
      "condition_list": [
        "Non Small Cell Lung Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "gem_cis": {
          "necitumumab_gem_cis": 0.8544711369213004
        },
        "necitumumab_gem_cis": {
          "gem_cis": 1.1703145452086854
        }
      },
      "min_hazard_ratio": 0.8544711369213004
    },
    {
      "identifier": "TANIA",
      "pubmed": "25273342",
      "registration": "NCT01250379",
      "publication_date": "2014-09-28 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 494,
      "weibull_by_arm": {
        "chem_bev": {
          "scale": 9.003055812937914,
          "shape": 1.3052287277478531
        },
        "chemo": {
          "scale": 7.039744143425513,
          "shape": 1.1590612250526213
        }
      },
      "weibull_max_diff": 0.7547233989574499,
      "time_scale": "Unknown",
      "title": "A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)",
      "condition_list": [
        "Breast Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "chem_bev": {
          "chemo": 1.3085136506574875
        },
        "chemo": {
          "chem_bev": 0.7642258829302476
        }
      },
      "min_hazard_ratio": 0.7642258829302476
    },
    {
      "identifier": "Tasquinimod",
      "pubmed": "27298414",
      "registration": "NCT01234311",
      "publication_date": "2016-06-13 00:00:00",
      "arms": 2,
      "disease": "prostate_cancer",
      "subjects": 1158,
      "weibull_by_arm": {
        "placebo": {
          "scale": 31.93362648373618,
          "shape": 1.2688051445194395
        },
        "tasq": {
          "scale": 29.17214308142884,
          "shape": 1.3406502308301753
        }
      },
      "weibull_max_diff": 0.927775819893474,
      "time_scale": "Months",
      "title": "A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer",
      "condition_list": [
        "Prostate Cancer"
      ],
      "data_index": {
        "age": [
          {
            "value_range": {
              "relation": "≤",
              "lower": null,
              "upper": 65.0
            },
            "groups": [
              {
                "group_name": "Tasquinimod",
                "count": 214,
                "percentage": 25.7
              },
              {
                "group_name": "Placebo",
                "count": 106,
                "percentage": 25.7
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 66.0,
              "upper": 75.0
            },
            "groups": [
              {
                "group_name": "Tasquinimod",
                "count": 371,
                "percentage": 44.6
              },
              {
                "group_name": "Placebo",
                "count": 186,
                "percentage": 45.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 76.0,
              "upper": 80.0
            },
            "groups": [
              {
                "group_name": "Tasquinimod",
                "count": 144,
                "percentage": 17.3
              },
              {
                "group_name": "Placebo",
                "count": 64,
                "percentage": 15.5
              }
            ]
          },
          {
            "value_range": {
              "relation": ">",
              "lower": 80.0,
              "upper": null
            },
            "groups": [
              {
                "group_name": "Tasquinimod",
                "count": 103,
                "percentage": 12.4
              },
              {
                "group_name": "Placebo",
                "count": 57,
                "percentage": 13.8
              }
            ]
          }
        ],
        "ecog": []
      },
      "hazard_ratios": {
        "placebo": {
          "tasq": 1.108740906561803
        },
        "tasq": {
          "placebo": 0.9019239698668576
        }
      },
      "min_hazard_ratio": 0.9019239698668576
    },
    {
      "identifier": "TCOG0701",
      "pubmed": "25908605",
      "registration": "UMIN000000608",
      "publication_date": "2015-04-23 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 596,
      "weibull_by_arm": {
        "docetaxel_cis": {
          "scale": 23.75578018621354,
          "shape": 1.261324726703294
        },
        "s1_cis": {
          "scale": 23.372078912244508,
          "shape": 1.2115068358993757
        }
      },
      "weibull_max_diff": 0.9721623042099504,
      "time_scale": "Months",
      "title": null,
      "condition_list": null,
      "data_index": {
        "age": [],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "S-1 plus cisplatin",
                "count": 151,
                "percentage": 50.2
              },
              {
                "group_name": "Docetaxel plus cisplatin",
                "count": 152,
                "percentage": 51.5
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "S-1 plus cisplatin",
                "count": 150,
                "percentage": 49.8
              },
              {
                "group_name": "Docetaxel plus cisplatin",
                "count": 143,
                "percentage": 48.5
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "docetaxel_cis": {
          "s1_cis": 1.0208267764660766
        },
        "s1_cis": {
          "docetaxel_cis": 0.9795981287460197
        }
      },
      "min_hazard_ratio": 0.9795981287460197
    },
    {
      "identifier": "TEXT-SOFT(2)",
      "pubmed": "24881463",
      "registration": "NCT00066703, NCT00066690 ",
      "publication_date": "2014-06-01 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 4690,
      "weibull_by_arm": {
        "exemestane_os": {
          "scale": 45.4460549557897,
          "shape": 1.0846042996061205
        },
        "tamoxifen_os": {
          "scale": 24.21524522233254,
          "shape": 1.2866366974887846
        }
      },
      "weibull_max_diff": 0.5618717357337745,
      "time_scale": "Unknown",
      "title": null,
      "condition_list": null,
      "data_index": {
        "age": [
          {
            "value_range": {
              "relation": "<",
              "lower": null,
              "upper": 35.0
            },
            "groups": [
              {
                "group_name": "No-Chemotherapy Cohorts, TEXT",
                "count": 41,
                "percentage": 3.9
              },
              {
                "group_name": "No-Chemotherapy Cohorts, SOFT",
                "count": 14,
                "percentage": 1.5
              },
              {
                "group_name": "Chemotherapy Cohorts, TEXT",
                "count": 191,
                "percentage": 11.9
              },
              {
                "group_name": "Chemotherapy Cohorts, SOFT",
                "count": 224,
                "percentage": 20.6
              },
              {
                "group_name": "Overall",
                "count": 470,
                "percentage": 10.0
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 35.0,
              "upper": 39.0
            },
            "groups": [
              {
                "group_name": "No-Chemotherapy Cohorts, TEXT",
                "count": 123,
                "percentage": 11.7
              },
              {
                "group_name": "No-Chemotherapy Cohorts, SOFT",
                "count": 68,
                "percentage": 7.2
              },
              {
                "group_name": "Chemotherapy Cohorts, TEXT",
                "count": 289,
                "percentage": 18.0
              },
              {
                "group_name": "Chemotherapy Cohorts, SOFT",
                "count": 312,
                "percentage": 28.7
              },
              {
                "group_name": "Overall",
                "count": 792,
                "percentage": 16.9
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 40.0,
              "upper": 49.0
            },
            "groups": [
              {
                "group_name": "No-Chemotherapy Cohorts, TEXT",
                "count": 768,
                "percentage": 72.9
              },
              {
                "group_name": "No-Chemotherapy Cohorts, SOFT",
                "count": 690,
                "percentage": 73.2
              },
              {
                "group_name": "Chemotherapy Cohorts, TEXT",
                "count": 1048,
                "percentage": 65.2
              },
              {
                "group_name": "Chemotherapy Cohorts, SOFT",
                "count": 515,
                "percentage": 47.4
              },
              {
                "group_name": "Overall",
                "count": 3021,
                "percentage": 64.4
              }
            ]
          },
          {
            "value_range": {
              "relation": "≥",
              "lower": 50.0,
              "upper": null
            },
            "groups": [
              {
                "group_name": "No-Chemotherapy Cohorts, TEXT",
                "count": 121,
                "percentage": 11.5
              },
              {
                "group_name": "No-Chemotherapy Cohorts, SOFT",
                "count": 171,
                "percentage": 18.1
              },
              {
                "group_name": "Chemotherapy Cohorts, TEXT",
                "count": 79,
                "percentage": 4.9
              },
              {
                "group_name": "Chemotherapy Cohorts, SOFT",
                "count": 36,
                "percentage": 3.3
              },
              {
                "group_name": "Overall",
                "count": 407,
                "percentage": 8.7
              }
            ]
          }
        ],
        "ecog": []
      },
      "hazard_ratios": {
        "exemestane_os": {
          "tamoxifen_os": 1.4389046025311047
        },
        "tamoxifen_os": {
          "exemestane_os": 0.6949731054032006
        }
      },
      "min_hazard_ratio": 0.6949731054032006
    },
    {
      "identifier": "TH3RESA",
      "pubmed": "24793816",
      "registration": "NCT01419197",
      "publication_date": "2014-05-02 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 602,
      "weibull_by_arm": {
        "physicians_choice": {
          "scale": 19.46448516717345,
          "shape": 1.3438003681576698
        },
        "trastuzumab_emtansine": {
          "scale": 26.69480858541251,
          "shape": 1.4345859598819282
        }
      },
      "weibull_max_diff": 0.7166714711117969,
      "time_scale": "Months",
      "title": "A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy",
      "condition_list": [
        "Breast Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "physicians_choice": {
          "trastuzumab_emtansine": 0.5451165935859678
        },
        "trastuzumab_emtansine": {
          "physicians_choice": 1.834469931325426
        }
      },
      "min_hazard_ratio": 0.5451165935859678
    },
    {
      "identifier": "TRAPEZE",
      "pubmed": "26794729",
      "registration": "ISRCTN12808747",
      "publication_date": "2016-01-21 00:00:00",
      "arms": 2,
      "disease": "prostate_cancer",
      "subjects": 757,
      "weibull_by_arm": {
        "no_sr89": {
          "scale": 12.081821893425497,
          "shape": 1.3307820817354248
        },
        "sr89": {
          "scale": 13.310362623526967,
          "shape": 1.21869872576313
        }
      },
      "weibull_max_diff": 0.9309857132792448,
      "time_scale": "Unknown",
      "title": null,
      "condition_list": null,
      "data_index": {
        "age": [],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "Economic analysis subset",
                "count": 291,
                "percentage": 41.16
              },
              {
                "group_name": "All TRAPEZE trial participants",
                "count": 305,
                "percentage": 40.29
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "Economic analysis subset",
                "count": 361,
                "percentage": 51.06
              },
              {
                "group_name": "All TRAPEZE trial participants",
                "count": 389,
                "percentage": 51.39
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 2.0,
              "upper": 2.0
            },
            "groups": [
              {
                "group_name": "Economic analysis subset",
                "count": 55,
                "percentage": 7.78
              },
              {
                "group_name": "All TRAPEZE trial participants",
                "count": 63,
                "percentage": 8.32
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "no_sr89": {
          "sr89": 0.8754058921477321
        },
        "sr89": {
          "no_sr89": 1.1423272438189638
        }
      },
      "min_hazard_ratio": 0.8754058921477321
    },
    {
      "identifier": "TRIBE",
      "pubmed": "26338525",
      "registration": "NCT00719797",
      "publication_date": "2015-09-01 00:00:00",
      "arms": 2,
      "disease": "colorectal_cancer",
      "subjects": 508,
      "weibull_by_arm": {
        "folfiri_bev": {
          "scale": 35.42038990328106,
          "shape": 1.4342449909818178
        },
        "folfoxiri_bev": {
          "scale": 40.93757664171625,
          "shape": 1.2920482584947715
        }
      },
      "weibull_max_diff": 0.8899083829206745,
      "time_scale": "Months",
      "title": "Combination Chemotherapy and Bevacizumab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer",
      "condition_list": [
        "Colorectal Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "folfiri_bev": {
          "folfoxiri_bev": 0.8360602363184663
        },
        "folfoxiri_bev": {
          "folfiri_bev": 1.1960860671994533
        }
      },
      "min_hazard_ratio": 0.8360602363184663
    },
    {
      "identifier": "TRIBE(2)",
      "pubmed": "25337750",
      "registration": "NCT00719797",
      "publication_date": "2014-10-23 00:00:00",
      "arms": 2,
      "disease": "colorectal_cancer",
      "subjects": 508,
      "weibull_by_arm": {
        "folfiri_bevacizumab": {
          "scale": 33.92298331450049,
          "shape": 1.5599327986594906
        },
        "folfoxiri_bevacizumab": {
          "scale": 39.28503173749985,
          "shape": 1.3863759771717665
        }
      },
      "weibull_max_diff": 0.8892850133412336,
      "time_scale": "Months",
      "title": "Combination Chemotherapy and Bevacizumab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer",
      "condition_list": [
        "Colorectal Cancer"
      ],
      "data_index": {
        "age": [],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "FOLFIRI plus Bevacizumab",
                "count": 229,
                "percentage": 89.5
              },
              {
                "group_name": "FOLFOXIRI plus Bevacizumab",
                "count": 227,
                "percentage": 90.1
              }
            ]
          },
          {
            "value_range": {
              "relation": "-",
              "lower": 1.0,
              "upper": 2.0
            },
            "groups": [
              {
                "group_name": "FOLFIRI plus Bevacizumab",
                "count": 27,
                "percentage": 10.5
              },
              {
                "group_name": "FOLFOXIRI plus Bevacizumab",
                "count": 25,
                "percentage": 9.9
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "folfiri_bevacizumab": {
          "folfoxiri_bevacizumab": 0.8349879823439391
        },
        "folfoxiri_bevacizumab": {
          "folfiri_bevacizumab": 1.19762202707738
        }
      },
      "min_hazard_ratio": 0.8349879823439391
    },
    {
      "identifier": "TROG0306",
      "pubmed": "27155740",
      "registration": "NCT00110162",
      "publication_date": "2016-05-04 00:00:00",
      "arms": 2,
      "disease": "prostate_cancer",
      "subjects": 293,
      "weibull_by_arm": {
        "delayed_adt": null,
        "immediate_adt": null
      },
      "weibull_max_diff": null,
      "time_scale": "Months",
      "title": "Androgen Deprivation Therapy in Treating Patients With Prostate Cancer",
      "condition_list": [
        "Prostate Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "delayed_adt": {
          "immediate_adt": 0.50026736185684
        },
        "immediate_adt": {
          "delayed_adt": 1.9989311241259171
        }
      },
      "min_hazard_ratio": 0.50026736185684
    },
    {
      "identifier": "TURANDOT",
      "pubmed": "27501767",
      "registration": "NCT00600340",
      "publication_date": "2016-08-05 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 564,
      "weibull_by_arm": {
        "bev_capecitabine": {
          "scale": 36.99175191066461,
          "shape": 1.253195464657852
        },
        "bev_paclitaxel": {
          "scale": 40.01565495955538,
          "shape": 1.3169501105900634
        }
      },
      "weibull_max_diff": 0.9114357766165914,
      "time_scale": "Months",
      "title": "2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab",
      "condition_list": [
        "Metastatic Breast Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "bev_capecitabine": {
          "bev_paclitaxel": 0.9040806823526071
        },
        "bev_paclitaxel": {
          "bev_capecitabine": 1.1060959707686608
        }
      },
      "min_hazard_ratio": 0.9040806823526071
    },
    {
      "identifier": "VANTAGE014",
      "pubmed": "25800891",
      "registration": "NCT00128102",
      "publication_date": "2015-03-20 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 661,
      "weibull_by_arm": {
        "placebo": {
          "scale": 10.449947303663231,
          "shape": 1.3045917050220586
        },
        "vorinostat": {
          "scale": 13.09548301197205,
          "shape": 1.2314642484059963
        }
      },
      "weibull_max_diff": 0.8114054122066279,
      "time_scale": "Unknown",
      "title": "Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)",
      "condition_list": [
        "Mesothelioma",
        "Lung Cancer"
      ],
      "data_index": null,
      "hazard_ratios": {
        "placebo": {
          "vorinostat": 0.7557110451409773
        },
        "vorinostat": {
          "placebo": 1.3232570920191469
        }
      },
      "min_hazard_ratio": 0.7557110451409773
    },
    {
      "identifier": "WJOG5108L",
      "pubmed": "27022112",
      "registration": "University Hospital Medical Information Network in Japan 000002014",
      "publication_date": "2016-03-28 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 559,
      "weibull_by_arm": {
        "erlotinib": {
          "scale": 32.560777497767255,
          "shape": 1.2437906990281196
        },
        "gefitinib": {
          "scale": 32.014239861410935,
          "shape": 1.2341303560267618
        }
      },
      "weibull_max_diff": 0.9809495707460612,
      "time_scale": "Months",
      "title": null,
      "condition_list": null,
      "data_index": {
        "age": [
          {
            "value_range": {
              "relation": "<",
              "lower": null,
              "upper": 65.0
            },
            "groups": [
              {
                "group_name": "Erlotinib",
                "count": 117,
                "percentage": 41.8
              },
              {
                "group_name": "Gefitinib",
                "count": 104,
                "percentage": 37.3
              },
              {
                "group_name": "All Patients",
                "count": 221,
                "percentage": 39.5
              }
            ]
          },
          {
            "value_range": {
              "relation": "≥",
              "lower": 65.0,
              "upper": null
            },
            "groups": [
              {
                "group_name": "Erlotinib",
                "count": 163,
                "percentage": 58.2
              },
              {
                "group_name": "Gefitinib",
                "count": 175,
                "percentage": 62.7
              },
              {
                "group_name": "All Patients",
                "count": 338,
                "percentage": 60.5
              }
            ]
          }
        ],
        "ecog": [
          {
            "value_range": {
              "relation": "=",
              "lower": 0.0,
              "upper": 0.0
            },
            "groups": [
              {
                "group_name": "Erlotinib",
                "count": 140,
                "percentage": 50.0
              },
              {
                "group_name": "Gefitinib",
                "count": 112,
                "percentage": 40.1
              },
              {
                "group_name": "All Patients",
                "count": 252,
                "percentage": 45.1
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 1.0,
              "upper": 1.0
            },
            "groups": [
              {
                "group_name": "Erlotinib",
                "count": 119,
                "percentage": 42.5
              },
              {
                "group_name": "Gefitinib",
                "count": 150,
                "percentage": 53.8
              },
              {
                "group_name": "All Patients",
                "count": 269,
                "percentage": 48.1
              }
            ]
          },
          {
            "value_range": {
              "relation": "=",
              "lower": 2.0,
              "upper": 2.0
            },
            "groups": [
              {
                "group_name": "Erlotinib",
                "count": 21,
                "percentage": 7.5
              },
              {
                "group_name": "Gefitinib",
                "count": 17,
                "percentage": 6.1
              },
              {
                "group_name": "All Patients",
                "count": 38,
                "percentage": 6.8
              }
            ]
          }
        ]
      },
      "hazard_ratios": {
        "erlotinib": {
          "gefitinib": 1.028987179832223
        },
        "gefitinib": {
          "erlotinib": 0.9718294062352173
        }
      },
      "min_hazard_ratio": 0.9718294062352173
    },
    {
      "identifier": "WJOG5208L",
      "pubmed": "26522337",
      "registration": "UMIN000002015",
      "publication_date": "2015-10-28 00:00:00",
      "arms": 2,
      "disease": "lung_cancer",
      "subjects": 349,
      "weibull_by_arm": {
        "cisplatin_docetaxel": {
          "scale": 5.927614140788438,
          "shape": 1.421976926991651
        },
        "nedaplatin_docetaxel": {
          "scale": 6.7896658295213035,
          "shape": 1.3412152745064247
        }
      },
      "weibull_max_diff": 0.8866903007831959,
      "time_scale": "Months",
      "title": null,
      "condition_list": null,
      "data_index": null,
      "hazard_ratios": {
        "cisplatin_docetaxel": {
          "nedaplatin_docetaxel": 0.8226812269491308
        },
        "nedaplatin_docetaxel": {
          "cisplatin_docetaxel": 1.215537643551739
        }
      },
      "min_hazard_ratio": 0.8226812269491308
    },
    {
      "identifier": "WSGAGO",
      "pubmed": "24827128",
      "registration": "NCT02115204",
      "publication_date": "2014-05-14 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 1930,
      "weibull_by_arm": {
        "control": {
          "scale": 333.5083842558971,
          "shape": 1.1367318414416796
        },
        "ed_doc": {
          "scale": 318.5511521131424,
          "shape": 1.3550152823215065
        }
      },
      "weibull_max_diff": 0.9939625315578966,
      "time_scale": "Unknown",
      "title": "4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF",
      "condition_list": [
        "Breast Cancer"
      ],
      "data_index": {
        "age": [
          {
            "value_range": {
              "relation": "<",
              "lower": null,
              "upper": 35.0
            },
            "groups": [
              {
                "group_name": "CMF",
                "count": 4,
                "percentage": 2.3
              },
              {
                "group_name": "FEC",
                "count": 37,
                "percentage": 4.7
              },
              {
                "group_name": "EC-Doc",
                "count": 37,
                "percentage": 3.8
              }
            ]
          }
        ],
        "ecog": []
      },
      "hazard_ratios": {
        "control": {
          "ed_doc": 0.7312952791887889
        },
        "ed_doc": {
          "control": 1.3674366954881472
        }
      },
      "min_hazard_ratio": 0.7312952791887889
    },
    {
      "identifier": "WSG-ARA",
      "pubmed": "24356620",
      "registration": "NR",
      "publication_date": "2014-01-01 00:00:00",
      "arms": 2,
      "disease": "breast_cancer",
      "subjects": 1170,
      "weibull_by_arm": {
        "da_negative": {
          "scale": 136.9486918790809,
          "shape": 1.4560535232995637
        },
        "da_positive": {
          "scale": 155.5572337964695,
          "shape": 1.3860668368451337
        }
      },
      "weibull_max_diff": 0.8916358661327319,
      "time_scale": "Unknown",
      "title": null,
      "condition_list": null,
      "data_index": {
        "age": [],
        "ecog": []
      },
      "hazard_ratios": {
        "da_negative": {
          "da_positive": 0.9126835478018845
        },
        "da_positive": {
          "da_negative": 1.0956700188235113
        }
      },
      "min_hazard_ratio": 0.9126835478018845
    }
  ]
}